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                                                           SUMMARY 
 
Two types of lactase deficiency exist in human, congenital lactase deficiency and adult-type 
hypolactasia. Congenital lactase deficiency (CLD) is an autosomal recessive severe 
gastrointestinal disorder in newborns characterized by watery diarrhoea after breast fed milk 
due to osmosis developed by unhydrolyzed lactose. The severe diarrhoea followed by 
dehydration, acidosis, and weight loss is usually diagnosed during the first weeks or months 
of life. CLD is considered one of the 36 rare monogenic disorders enriched in Finnish 
population. In contrast, adult-type hypolactasia is a normal physiological condition, in which 
the lactase deficiency is a result of the down regulation of the lactase enzyme after weaning 
in mammals including human. The condition can be clinically presented with a wide diversity 
of intestinal symptoms such as: meteorism, borborgymi, flatulence, fullness, abdominal 
colicky pains, loose stools and diarrhoea after ingestion or eating lactose containing foods. 
 
In this study we localized the CLD locus between markers D2S114 and D2S132 on 
chromosome 2q in 19 CLD families. Further we fine mapped the locus based on linkage 
disequilibrium (LD) and ancestral haplotype analyses between markers D2S314-D2S2385, 
about 1 Mb 5´ of the lactase-phlorizin hydrolase (LPH) gene. Further we localized the locus 
for adult-type hypolactasia on a 6 cM region flanking the LPH gene between markers 
D2S114-D2S2385 in nine extended Finnish families. Using linkage disequilibrium and 
haplotype analysis we restricted the region to 47 kb interval between markers D2S3014-
D2S3012. Sequence analysis of this region revealed two variants, C/T-13910 and G/A-22018 that 
show significant correlation with lactase persistence /non persistence trait in Finnish families 
and lactase enzyme activity in case-control study materials. Mutational analysis of the 
variants C/T-13910 and G/A-22018 associated with lactase persistence revealed no correlation 
with CLD and provided evidence that two separate genetic loci underlying congenital lactase 
deficiency and lactase persistence, respectively, are present on 2q21. Both molecular 
epidemiological studies in different populations and recent functional studies show that C/T-
13910 variant is most probably the causative variant of lactase persistence trait.  
 
The analysis of disaccharidase activities shows that the mean level of lactase activity among 
CC-13910 genotype was 6.86±0.35 U/g, CT-13910 genotype it was 37.8±1.4 U/g, and 57.6±2.4 
U/g protein for the TT-13910 genotype and age per se has no significant effect on the 
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disaccharidase activity in adults. Further, relative quantitation of the expressed LPH alleles in 
the intestinal mucosa showed that the mRNA levels in individuals with the T-13910 allele 
several times higher compared to that found in individuals with the C-13910 allele, suggesting 
regulation of the LPH gene at the transcriptional level. To trace back the age and origin of 
lactase persistence mutation haplotype analysis was performed using SNPs flanking the 
associated SNPs and covering 30 kb region in 37 populations. Haplotype analysis revealed 
that two major haplotypes could be identified as carrying the lactase non persistent variant 
whereas only one major background haplotype was observed in lactase persistent alleles in all 
populations studied. Based on haplotype analysis and LD in global populations we propose 
that the geographic region west of the Ural Mountains represents the most likely origin of the 
major global lactase persistence mutation. The major lactase persistent haplotype most 
probably originated in a nomadic population tribes some (4800-6600 years ago) and the 
mutation then spread with migration of tribes westward towards Europe as well as to the 
south to Western Asia and Middle East. This would imply that lactase persistence was 
introduced to Europe by migrations of Indo-European tribes from Asian Steppes, not from 
Middle East, the region where farming and dairy practice are supposed to originate. 
 
Significant correlation of the C/C-13910 genotype with low lactase activity, lactase/sucrase 
(L/S)-ratio and the similar prevalence figures of C/T-13910 with lactase persistence in >30 
populations studied facilitated the introduction of a genetic test of adult-type hypolactasia to 
clinical practice. Identification of the C/T-13910 polymorphism has facilitated large-scale 
population based studies on the effect of lactase persistence/non-persistence on different 
clinical conditions like diabetes and osteoporosis. For example, the analysis of 1455 patients 
with type I and 615 with type II diabetes and 446 non diabetic controls in the Finnish 
population shows no detected differences in the lactase persistence genotype frequencies 
(C/T -13910 and TT-13910) between diabetic and non diabetic subjects. Thus, we conclude that 
the C/T-13910 polymorphism associated with lactase persistence is not a risk factor for type I or 
type II diabetes in the Finnish population. In addition, the data that emerged from the analysis 
of the genetic variation of the LPH locus will help to shed light on the history of lactase 
persistence and provide the basis for analyses of evolutionary forces which have made the 
variant a predominant allele among some populations. 
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                            REVIEW OF THE LITERATURE 
 
1. LACTASE-PHLORIZIN HYDROLASE (LPH) 
 
Lactase-phlorizin hydrolase (LPH) (EC 3.2.1.23/62) is an integral glycoprotein of the 
microvillus membrane of small intestinal epithelial cells (Mantei et al. 1988). The mature 
enzyme has two enzymatic activities: Lactase (β-d-Galactoside galactohydrolase) (EC 3.2.1. 
23), and the phlorizin hydrolase (glycosyl-N-acyl-sphinosine glycohydrolase) (EC .3.2.1 62) 
(Schlegel-Haueter et al. 1972; Colombo et al. 1973; Skovbjerg et al. 1981; Skovbjerg et al. 
1982). Both catalytic activities are produced by a single polypeptide chain (Mantei et al. 
1988). 
 
Lactase is an enzyme responsible for hydrolysing the milk sugar lactose (the main 
carbohydrate in mammalian milk) to glucose and galactose (Figure 1) whereas, Phlorizin 
hydrolase is responsible for hydrolysing aryl and alkyl β- glycosides to phlorizin and β-
glycosylceramides (which are part of diet of most vertebrates) (Lorenz-Meyer et al. 1972; 
Keller P 1993; Arola and Tamm 1994). 
Lactose
Glucose Galactose
Lactase-Phlorizin hydrolase
Figure 1. The milk sugar, lactose, is hydrolyzed in the small intestinal epithelial cells to glucose and galacatose, by the 
enzyme lactase-phlorizin hydrolase.
Small intestinal epithelial cells
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1.1   Biosynthesis & Structure of lactase-phlorizin hydrolase 
 
Intestinal epithelial cells synthesize LPH as a single- chain large precursor protein (Pro LPH) 
with a molecular weight of 215 KDa (Danielsen et al. 1984; Skovbjerg et al. 1984; Naim et 
al. 1987). This precursor post-translationally processed to the mature LPH of molecular 
weight about 135-160 KDa. The pro-LPH protein consists of five domains: an N-terminal 
signal sequence (19 amino acids), a LPHα profragment size of 849 amino acids (none of 
which appear in mature, membrane bound LPH), for which the cellular destination is not 
known, an extracellular domain of 1104 amino acids, LPHβfinal,  (which carry both active sites 
of the enzymes), a hydrophobic trans-membrane anchor domain (19 amino acids) near the 
carboxy terminus, and short C-terminal cytosolic domain of 26 amino acids (Mantei et al. 
1988) Figure 2.  
 
The activity and the structure of the disacchridases are modulated by various mechanisms. 
Through a multi-step synthesis and the migration of the enzyme to the brush-border 
membrane, the mature enzyme gets localized to its site of action. This process is influenced 
by numerous factors, such as age, degree of differentiation of cells along the villus, 
glycosylation, and enterocyte life span. The glycosylation of the polypeptide is apparently 
similar to other disaccharidases (Danielsen et al. 1981; Roth 1987) and includes two main 
steps: the co-translational acquisition of glucan units of a high mannose type at the ER and 
subsequent trimming and complex glycosylation in the Golgi apparatus. During its passage 
through the Golgi complex, the intestinal brush-border hydrolases also get glycosylated with 
O-linked oligosaccharides. There is evidence that lactase is O-glycosylated through serines 
and threonine as well as N-glycosylated (through aspargine), and this glycosylation probably 
affects enzymatic activity as well as folding and intracellular transport (Naim and Lentze 
1992).  
 
Pro-LPH is glycosylated in the endoplasmic reticulum (ER) by mannose rich N-linked 
oligosaccharides (Naim and Naim 1996). In ER, two mannose rich pro-LPH homodimers 
form a dimer that is further transferred to the Golgi apparatus. The O-linked sugars of pro-
LPH dimer are glycosylated and N-linked sugars are further processed in cis-Golgi resulting 
in a glycoprotein with a molecular weight of 230 KDa (Hauri et al. 1985; Naim et al. 1991). 
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The mature pro-LPH undergoes two proteolytic cleavage steps: The first cleavage occurs 
intracellularly and removes the large LPHα profragment at Arg734/Leu735 resulting in a 
membrane bound LPHβintial (Leu735-Tyr1927)(von Heijne 1986; Jacob et al. 2000). 
 
Although details have been disputed, it is now considered that the active site at Glu1273 in 
domain III is responsible for hydrolysis of glucosides such as phlorizin, whereas the other in 
domain IV, at Glu1749, catalyzes the hydrolysis of galactosides such as lactose (Arribas et al. 
2000). LPHβintial is targeted to the intestine brush border membrane where it is cleaved by 
trypsin at Arg868/Ala869 leading to a 160 KDa mature LPHβfinal enzyme (Figure. 2) (Naim and 
Naim 1996; Wuthrich et al. 1996). LPH is anchored to the intestinal membrane by a 
hydrophobic region near its carboxy terminus  in the Cin-Nout orientation and the catalytic 
sites of the enzyme are located in the lumen of the intestine (Mantei et al. 1988). 
 
I II III IV
LPHβ finalLPHα pro-fragmentSS MA CT
Signal 
sequence
Membrane 
anchor
Cytoplasmic
tail 
Arg734 – Leu735
1st cleavage
Arg868 – Ala869
2nd cleavage
Conserved region
Figure 2.  The structure of pro-LPH in human. The  pro-LPH contains a cleavable signal sequence from Met1 to Gly19 that
guides the Polypeptide to endoplasmic reticulum (ER) (von Heijne 1986; Mantei et al 1988). The region from Ser20 to 
Thr1882 consists of  Four homologous domains (I-IV). The pro-LPH is processed by two proteolytic cleavages: an 
intracellular cleavage occurs between Arg734 and Leu735 which produces LPH β initial and a cleavage in the intestinal 
lumen between Arg868-Ala869 generates LPH βfinal the mature enzyme (Jacob et al 1996; Wüthrich et al 1996). Modified 
from (Jacob et al 2000).
LPHβ initial
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The LPH gene has been mapped to the long arm of chromosome 2q21 (Kruse et al. 1988; 
Harvey et al. 1993). The gene is approximately 55 kb in size and composed of 17 exons. The 
size of cDNA is 6274 nt, including the 5781 nucleotide coding for 1927 amino acids of the 
primary translation product (pro-LPH) (Mantei et al. 1988). There are four (I-IV) conserved 
structural and functional regions in the pro LPH polypeptide of which two (I-II) are deleted 
via proteolytic cleavages from the final LPH molecule (Figure 2). Mantei and colleagues 
(1988) suggest that the regions III-IV are result of gene duplication of the I-II regions of an 
ancestor gene. Sequence similarities of I-IV regions of the pro-LPH to β-glycosidases found 
in archaebacteria, eubacteria, and fungi support this hypothesis and thus, LPH probably 
belongs to the β-glucosidase and β-galactosidase superfamily (Naim 2001). 
 
 
1.2   Regulation of lactase-phlorizin hydrolase 
 
The regulation of LPH expression in both humans and animals has been studied extensively 
during past 20 years, greatly stimulated by the interest of the 2 phenotypes of lactase status in 
human, persistence and non persistence. However, the molecular mechanisms behind the 
developmental down regulation of LPH expression after infancy have remained unclear (Sahi 
1978; Sahi 1994b; Swallow 2003). 
 
There is accumulating evidence that the primary mechanism behind the developmental down-
regulation of the LPH expression might be mainly transcriptional (Escher et al. 1992; Lloyd 
et al. 1992; Fajardo et al. 1994). This has been shown in humans (Fajardo et al. 1994; Wang 
et al. 1995), rabbits (Keller et al. 1992), sheep (Lacey et al. 1994), pigs (Torp et al. 1993), and 
rats (Buller et al. 1990; Duluc et al. 1993; Krasinski et al. 1994). In the majority of cases, the 
LPH mRNA levels have been shown to correlate with lactase activity or the ratio of lactase to 
sucrase (L/S) activities (Escher et al. 1992; Lloyd et al. 1992; Fajardo et al. 1994). However, 
a comparison of LPH mRNA levels and lactase activity/LPH mRNA level ratios revealed a 
heterogeneous pattern in both hypolactasic (lactase non persistence) and lactase persistent 
individuals (Rossi et al. 1997). Further, biosynthesis of proLPH has been found to correlate 
with lactase mRNA levels but not with lactase activity in rabbits and rats, suggesting that a 
significant control of lactase gene expression could take place at the posttranscriptional level 
(Sebastio et al. 1989). Therefore, it has been suggested that the regulation of LPH gene 
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expression involves both transcriptional and posttranscriptional control (Freund et al. 1991; 
Maiuri et al. 1994; Rossi et al. 1997). 
 
Both a delayed posttranslational processing or/and reduction of pro-LPH synthesis have been 
observed in metabolic labelling studies in cells of hypolactasic individuals (Sterchi et al. 
1990; Witte et al. 1990; Lloyd et al. 1992), however, the transcriptional regulation is most 
probably the most important factor affecting the level of LPH. A number of cis elements with 
a putative role in LPH transcription have been identified in the DNA sequences immediately 
upstream of the TATA box of the promoter. The human, rat, and pig promoter show stretches 
of homology in this region. The binding sites for transcription factor binding sites are 
clustered within 100 bp upstream of a TATA box, as is the case for most genes (Figure 3).  
 
LPH 
ATGMCM6
Exon 16
Human
Pig
Rat
Mouse
MCM6
ATG
G/A-22018
100 bp homology
Figure 3. The species comparison shows a short segment (100 bp) have been conserved in different species just 5`LPH gene. 
This segment have been shown to be involved in interaction with different transcription factors to modulate the LPH 
Transcription. Whereas the region flanking the SNPs C/T-13910 and G/A-22018 does not shows any conservation.
C/T-13910
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The expression of the LPH gene is regulated by multiple transcription factors and their 
interactions which all influence the decline of the LPH enzyme after childhood. The effects 
of multiple transcription factors in the activation of the LPH promoter have been studied 
using transfection of reporter constructs, yeast one-hybrid cloning, and gel shift assays 
together. Specific antibodies, introduction of specific mutations, and co-transfection 
experiments with transcription factors, show evidence of the involvement of the caudal 
homologue Cdx2, HNF1α, HOX11, FREACs and GATA 4, 5 and 6 factors (Troelsen et al. 
1992; Troelsen et al. 1994b; Troelsen et al. 1997; Fitzgerald et al. 1998; Hollox et al. 1999; 
Spodsberg et al. 1999; Fang et al. 2000; Mitchelmore et al. 2000; Fang et al. 2001; Krasinski 
et al. 2001; van Wering et al. 2002a; van Wering et al. 2002b; Troelsen et al. 2003a). 
 
Analyses of pig and the rat LPH promoters in transgenic mouse models have indicated that 
approximately 1 kb 5´flanking sequence of the pig promoter and approximately 2 kb 
5´flanking sequence of the rat promoter are sufficient to produce the reporter gene expression 
in a pattern similar to the endogenous LPH expression (i.e. small intestinal-specific 
expression down regulation after weaning, and a correct expression pattern along the 
longitudinal axis of the small intestine) (Troelsen et al. 1994a; Krasinski et al. 1997; Lee et 
al. 2002). 
 
1.3   Terminology and classification of human lactase deficiencies 
 
The types of lactase deficiency (Villako and Maaroos 1994) can be divided into: 
a) Primary lactase deficiency: in which the lactase enzyme is selectively deficient. 
 There are two types of primary lactase deficiency:  
    i) Congenital lactase deficiency: lactase enzyme is almost nonexistent in the intestine of  
        the newborn. 
    ii) adult-type hypolactasia (lactase non persistence): lactase enzyme is physiologically  
        decreased (down-regulated) in adulthood to a level about 1/10 of that in newborn. 
Although, the two types are considered as primary types of lactase deficiency; we should 
stress the fact that the first one is a pathological condition, whereas the second one can be 
considered to represent a physiological condition.  
b) Secondary lactase deficiency: the lactase enzyme activity is affected with other 
disacchridase enzymes of the intestinal epithelial cells. 
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This type of lactase deficiency is usually due to an injury to intestinal mucosa. Injuries can be 
the result of diseases like in inflammatory bowel disease, Coeliac disease (Kosnai et al. 
1980), acute enteritis (Ulshen and Rollo 1980), Tropical sprue or parasitic infections like 
Giardia lamblia, and Ascaris lumbricoides (Carrera et al. 1984). Also severe protein 
deficiency (Brunser et al. 1976), and oral medicines like neomycin, colchicines, or gamma 
irradiation can result in the severe injury of intestinal mucosa and lead to secondary 
deficiencies of several intestinal disacchridase enzymes. 
 
Before we go on pause is necessary to clarify the terminology used. Sahi recommend the 
following accurate terminology (Sahi 1978) to describe lactase activity-related phenotypes: 
Hypolactasia is a very low activity of lactase in jejunal mucosa. Adult-type hypolactasia is 
used to differentiate from congenital lactase deficiency which affects the newborn.  
 
Table 1. Frequently used terms for lactase activity related-phenotypes. 
 
Low lactase activity 
 
Normal lactase activity 
 
Lactase non-persistence 
 
Lactase persistence 
 
Hypolactasia 
 
 
Adult-type hypolactasia 
 
 
Lactase restriction 
 
 
Alactasia 
 
 
Lactose malabsorption 
 
 
Lactose maldigestion 
 
 
Low lactose digestion capacity (low LDC) 
 
High lactose digestion capacity (high LDC) 
 
Lactose intolerance 
 
 
Milk intolerance 
 
 
 
Some have recommended the term lactase restriction rather than hypolactasia (Flatz 1987). 
The terms lactase deficiency and alactasia imply a total lack of lactase activity, which does 
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happen even in congenital lactase deficiency. As a counter part for hypolactasia, the term 
lactase persistence instead of hyperlactasia has been used, meaning moderate or high lactase 
activity in intestinal mucosa of adults. Since lactase persistence is the most common term 
used, then lactase non persistence should be used instead of hypolactasia. The terms lactose 
malabsorption and lactose maldigestion are used to describe a poor lactose hydrolyzing 
capacity which can be determined by lactose tolerance test. It almost always implies 
hypolactasia, so in practice these terms are often interchangeable. Flatz recommends the 
terms low lactose digestion capacity (Low LDC) and its counterpart high lactose digestion 
capacity (high LDC). Although these are the proper and accurate terms, they are somewhat 
cumbersome to use. The most common public term used is lactose intolerance to mean           
lactose malabsorption or adult-type hypolactasia with abdominal symptoms. However there 
are some lactase persistence people who have abdominal symptoms and via vice versa some 
hypolactasic people who do not have any symptoms. Another confusing term is milk 
intolerance which means that a person suffers from abdominal symptoms after milk 
ingestion. Finally, we should remember to differentiate between primary hypolactasia, 
mention above, and secondary hypolactasia which could appear due to infection or 
infestation of small intestine, in celiac disease. In these cases the histology of intestine is 
often abnormal and affects all diasaccharidases. 
 
In the following text the terms lactase nonpersistence/persistence will be used except in some 
situation where the term adult-type hypolactasia will be used instead of lactase 
nonpersistence. 
 
 
2. Congenital lactase deficiency 
 
2.1 Historical background 
 
Congenital lactase deficiency (CLD), (MIM 223000) (http://www.ncbi.nlm.nih.gov/omim) is 
an autosomal recessive inherited severe gastrointestinal disorder in newborns. Holzel et al 
(1959) described the first patients, two siblings who had watery diarrhoea from birth and a 
very low lactase activity in small intestine (Holzel et al. 1959). In 1966 Launiala et al 
reported a selective absence of lactase activity in duodenal specimens of infants with severe 
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diarrhoea after breast feeding (Launiala et al. 1966). In a clinical study on 16 patients 
Savilahti et al obtained the first evidence for recessive mode of inheritance for CLD 
(Savilahti et al. 1983).  
 
CLD is a rare inborn error that is most prevalent in the Finnish population (Asp et al. 1973; 
Asp and Dahlqvist 1974; Savilahti et al. 1983).The incidence of CLD have been estimated to 
be 1:60000 in the Finnish population (Savilahti E, personal communication). Subsequently, 
CLD is considered one of the 36 rare monogenic disorders enriched in Finnish population 
(Norio et al. 1973; Norio 2003a; Norio 2003b; Norio 2003c). So far, 46 patient in 39 families 
have been diagnosed in Finland (Savilahti et al. 1983), (personal communication) whereas 
only 18 cases have been reported elsewhere in the world (Holzel 1967). In 1991, Poggi et al 
have been reported in an ASHG meeting that complete sequence of LPH gene (the candidate 
gene) in one CLD patient (from our series) revealed no pathological sequence changes could 
be detected in LPH gene (Poggi and Sebastio 1991), but no further report has been shown, 
and the causative gene remained however unclear. 
 
 
2.2 Clinical presentations of CLD 
 
The hallmark symptom of CLD is watery diarrhoea that the newborn develops soon after the 
first doses of breast fed milk due to osmosis developed by unhydrolyzed lactose. The severe 
diarrhoea followed by dehydration, acidosis, and weight loss are usually diagnosed during the 
first weeks or months of life (Savilahti et al. 1983). Despite the symptoms, CLD infants are 
vigorous, and hungry. The child may survive for several months and the baby shows delayed 
growth due to loss of nutrients, dehydration and acidosis. In laboratory investigation, the 
faeces are strongly acidic, and contain large amount of lactose. Blood cholesterol is below 
normal. Low lactase activity is pathognomic. The activity of both sucrase and maltase is 
normal. Lactase activity measured in duodenal biopsy specimen is very low (0-10 U/g 
protein). After the child is put on lactose -free diet, diarrhoea stops and infant quickly begin 
to gain weight. In long term follow up studies of 16 cases, normal psychomotor development 
and growth of the affected children on lactose free diet have been observed (Savilahti et al. 
1983). In a series of 11 infant diagnosed of CLD at 6 to 88 days of life, hypercalemia and 
nephocalcinosis has been reported in which the hypercalcemia has been responded to 
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treatment within one week of the start of lactose free-diet in most patients (Saarela et al. 
1995). The mechanism of hypercalcemia is unclear but at the follow up examinations at ages 
2 to 10 years of age, one of the patient still had hypercalciuria, three of 11 was still had 
nephrocalcinosis. 
 
CLD should be differentiated from other very rare condition severe familial lactose 
intolerance (MIM 150220), where activity of lactase in new born is normal. In this condition 
symptoms vomiting, lactosuria and aminoaciduria develop during the first days of life  
(Holzel et al. 1962; Berg et al. 1969; Villako and Maaroos 1994).  
 
 
2.3 The Finnish disease heritage 
 
Although the prevalence data for CLD is globally not highly reliable, this very rare inborn 
error seems to be slightly more common in Finland than elsewhere (Asp et al. 1973; Asp and 
Dahlqvist 1974; Savilahti et al. 1983) and therefore it is considered to belong to the so called 
Finnish Disease Heritage (FDH). FDH is a group of rare hereditary diseases that are 
overrepresented in Finland (Norio 2003a). The reason for this is the peculiar history of 
Finland, small founder populations with long time isolation due to geographical and linguistic 
factors. This has resulted so far in the enrichment of about 36 monogenic disorders in this 
population. Characteristically, there is one founder mutation which is responsible for the 
distinct majority of disease alleles (Norio et al. 1973; Norio 2003a; Norio 2003b; Norio 
2003c). The high quality health care system with comprehensive population registers have 
provided the means for the clinicians and geneticists in Finland to identify these cases and to 
describe the concept of Finnish Disease Heritage concept (Norio et al. 1973). The incidence 
of these disorders varies mostly between from 1:10000 to 1:100000. The combined carrier 
frequency of all tested Finnish mutations in one DNA array based study monitored for the 
prevalence of 31 rare and common disease mutation varied between 1:11 and 1:6 in regional 
study populations (Pastinen et al. 2001). The variation of carrier frequency of different 
mutations within the country provides evidence for the relatively recent population 
bottlenecks (Pastinen et al. 2000; Pastinen et al. 2001).  
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When tracing the early Finns, the genetic data implies that the majority of the Finnish gene 
pool originate from later small founder populations of Indo-European speakers who arrived 
from the south approximately 2000 years ago (Varilo 1999) . It is actually more probable that 
small immigration groups arrived in Finland continuously after glacial period (Peltonen et al. 
1999). Analyses of the genetic diversity of the Y chromosome and mitochondrial DNA show 
that Finns differ from other European populations in having an exceptionally reduced amount 
of Y-chromosomal and mitochondrial diversity. This indicates that relatively few people have 
contributed to the genetic lineage of today´s Finns (Sajantila et al. 1996). Based on Y 
chromosomal haplotype studies, Finland has been inhabited in two waves (Kittles et al. 
1998). The first migratory wave of Uralic speakers from the east occurred some 4000 years 
ago and has had a distinct effect on the Finnish gene pool. A review the history of Finland 
reveals that for hundreds of years Finland remained very sparsely populated. In the 12th 
century the population was only 50000, by the 16th century the population had expanded to 
250000 but was still concentrated in the coastal areas. The internal migration in the 16th 
century resulted in the foundation of regional sub isolates and expansion of local populations 
shows existence for several bottle necks. The most severe was the great famine at the end of 
17th century that killed one third of the population of 400000 between the years 1690-1730. 
Since then the population has grown rapidly to today's 5.2 million inhabitant over three 
centuries. As a consequence of regional expansion most diseases belonging to the FDH 
present a regional clustering. A distribution equal to the population density indicates that the 
mutation is old (like diastrphic dysplasia and Meckel syndrome), whereas a tight regional 
distribution suggests a more recent introduction of the mutation.  
 
So far, out of the 36 diseases, the gene has been mapped in 33 (92%) and characterized in 27 
(75%). The founder mutation was responsible for the majority of disease genes. Among the 
27 characterized FDH genes, the main mutation is found in 100% of the chromosomes in 8 
disorders. In most of the others, one mutation is represented in more than 90% of the disease 
alleles. In two diseases, the corresponding fraction is 70% (Peltonen et al. 1999; Norio 
2003b). Strong evidence of the descent of many Finnish disease genes from a single founding 
ancestor has been obtained from linkage disequilibrium and haplotype data. Long LD 
intervals reaching up to 13 cM (Peltonen et al. 1999) around a particular disease mutation, 
have been observed and used as a very powerful tool by geneticist to tackle the molecular 
background of FDH. An update of the mutations behind the Finnish disease Heritage can be 
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obtained in references (Peltonen et al. 1999; Norio 2003c) and on the website 
(www.findis.org). 
 
 
3.  Lactase persistence/nonpersistence 
 
3.1 Historical background  
 
Lactose, the milk sugar, has been found in 1860s to cause diarrhoea in dogs (Sahi 1994b). In 
the beginning of 20th century it was shown that lactase enzyme was present in intestine of 
infant animals and greatly diminished in adult animals (Mendel 1907; Kretchmer 1971; Sahi 
1994b). The developmental curve for the lactase enzyme was constructed for a number of 
animals including rat, mouse, dog, pig, and rabbit (Heilskov 1951), in which the activity was 
high in infancy and then on weaning the lactase activity was down regulated to one tenth the 
level in newborn in adult animals. In contrast, there were only a few direct observations of 
human intestinal lactase activity (Sahi 1994b). The activity was established during infancy 
but it was sharply reduced by severe disease. There is consensus that the small intestinal 
mucosa is the principal site of lactase activity, which is highest in jejunum. However, 
controversy existed on the precise site of enzyme activity until Borgstöm et al (Borgstrom et 
al. 1957) and Dahlqvist et al (Dahlqvist and Borgstrom 1961) showed that the hydrolysis of 
lactose takes place in the outer membrane (brush border) of the mucosal epithelia cells. 
 
Low lactase activity in healthy adults humans was discovered independently by two groups in  
1963 (Auricchio et al. 1963; Dahlqvist et al. 1963). In those early days most of the studies 
were conducted on subjects from Northern Europe, among whom lactase persistence is 
common. This led to belief that lactase activity remains throughout the life span in human, 
and the term adult-type hypolactasia was coined to indicate the low lactase activity in the 
jejunal mucosa in healthy adults. When the studies expand to other populations it turned out 
that the hypolactasia is prevalent in adulthood in the most other groups and represents the 
normal state for humans like in other mammals (Sahi 1994b). 
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3.2 Diagnosis of lactase nonpersistence (adult-type hypolactasia) 
 
Hypolactasia per se does not give to any disturbance; symptoms appear only after ingestion 
of lactose containing foods. In nonpersistent subjects foods containing lactose causes 
abdominal symptoms such as meteorism. borborgymi, flatulence, fullness, abdominal colicky 
pains, loose stools and diarrhoea (Villako and Maaroos 1994). There is a considerable 
individual variation in the manifestation of symptoms; this depends on the amount of milk 
products consumed and the individual sensitivity to stomach pains.  
 
Strictly speaking there are two types of tests for diagnosing hypolactasia, direct and indirect 
methods (Metz et al. 1975; Newcomer et al. 1975; Flatz and Rotthauwe 1977; Arola 1994). 
1) The direct method is an invasive method in which in which intestinal biopsy specimen 
processed for an assay of mucosal disaccharides. The disaccharidase assay is performed 
according to the standard method developed mainly by Dahlqvist & Burgess (Dahlqvist 
1964). Diagnosis of hypolactasia is suggested when the lactase activity < 10 IU/g protein and 
lactase/sucrase ratio <0.3 with normal histology. There are different cut-off values used by 
different laboratories, in the Finnish samples analyzed in this thesis, a cut-off value of < 20 
IU/g protein for lactase activity was used. 
2) Indirect methods which are based on lactose tolerance tests.  
There are many different tests but the two used worldwide are the following: 
a) Lactose tolerance test (LTT) is based on the measurements of the increase in blood glucose 
by serial determinations after oral lactose load. Lactose dose varies in different modifications 
from physiologic dose of 12.5 g to the usual tolerance dose of 50 g. An increase to values < 
1.1 mmol/l has been considered as indicative of hypolactasia whereas an increase to values 
>1.7 mmol/l is considered to indicate lactase persistence. To increase the reliability of the test 
a LTT with ethanol (LTTE) to inhibit the conversion of galactose to glucose by liver has been 
used by Sahi in the diagnosis of the family subjects (Sahi 1974a) involved in the present 
study. Hypolactasia is diagnosed if the blood galactose concentration is < 0.03 mmol/l at 40 
min after lactose and ethanol ingestion. 
b) Breath hydrogen test after lactose ingestion (BHT), hydrogen concentration in expired air 
is determined by gas chromatography after oral lactose load. Samples are taken at zero time 
point and then at intervals of 15 to 60 min for 2 to 6 hours. An increase in hydrogen 
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concentration > 20 ppm or > 0.3 ml/min over baseline is interpreted as a diagnostic for 
hypolactasia (Metz et al. 1975; Arola 1994).  
 
As stated before, the average sensitivity of traditional laboratory tests (lactose tolerance test, 
breath-hydrogen test) vary between 69% to 100% (Arola 1994). The conflicting reports are 
complicated by the fact that the correlation between lactose intolerance and lactase non 
persistence is poor; depending on the test used, 11% to 32% of individuals with lactase non 
persistence report no symptoms from lactose containing milk products (Carroccio et al. 1998; 
de Vrese et al. 2001), whereas up to 57% of subjects with self-reported lactose intolerance 
have normal lactose absorption in breath-hydrogen test (Carroccio et al. 1998; Saltzman et al. 
1999). The development of lactose intolerance per se seems not only to be related to the 
lactase enzyme level i.e. hypolactasia, but other factors interact in complex network to 
produce the clinical symptoms. 
 
 
3.3 Genetics of lactase persistence/nonpersistence 
 
The decline in lactase activity to a very low level after infancy remained unclear for a long 
time until in 1963 isolated intestinal lactase deficiency in adults was reported (Auricchio et 
al. 1963; Dahlqvist et al. 1963) and an accurate enzymatic method for intestinal disaccaridase 
determinations was published (Dahlqvist 1964). Since then, two hypotheses underlying the 
down regulation of lactase in adults have been suggested the adaptive and the genetic 
hypothesis.  
 
The adaptive hypothesis suggests that lactase enzyme activity depends on lactose feeding 
and they propose that the hypolactasia appears merely because of the lack of milk supply (the 
major lactose source) (Bolin et al. 1969; Bolin and Davis 1970; Bolin et al. 1971). Animal 
feeding experiments have been carried out using rats, calves and pigs. Most of studies have 
fail to show any adaptation (Sriratanaban et al. 1971; Lebenthal et al. 1973; Leichter 1973). 
In none of the studies lactose feeding able to prevent the normal post weaning decline in 
lactase activity (Bolin et al. 1969; Lebenthal et al. 1973). Feeding trials in humans also have 
shown that feeding lactose in diet does not prevent the down regulation, and the lack of 
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lactose in diet does not provoke a decline in lactase activity (Kretchmer 1971; Gilat et al. 
1972).  
 
In contrast, family studies have suggested a genetic aetiology behind the decline in lactase 
activity (Ferguson and Maxwell 1967; Welsh 1970; Gilat et al. 1973). The genetic 
hypothesis suggests that the decline in lactase activity in adult is genetically defined and not 
related to lactose feeding. Recessive inheritance of lactase decline, adult-type hypolactasia, 
was supported by family studies (Ferguson and Maxwell 1967; Welsh 1970; Gilat et al. 1973; 
Sahi et al. 1973; Sahi 1974a), a twin study (Metneki et al. 1984), and the distribution in 
disaccharidase activity (Ho et al. 1982; Flatz 1984). Strong evidence for recessive inheritance 
was supported by family studies in Finnish population (Sahi et al. 1973; Sahi 1974a). This 
study involved 11 probands and 327 family members (on which our study is also based). In 
this material the most valid indirect diagnostic method was used; the lactose tolerance test 
with ethanol which allowed the researchers to perform a reliable characterization of the 
phenotype of all family members and conclusive pedigree analysis. 
 
Once it had been shown that adult-type hypolactasia is genetically determined recessively 
inherited trait (Ferguson and Maxwell 1967; Sahi et al. 1973; Sahi 1974a), the search for the 
causing factors intensified. In 1988 the human lactase gene was mapped to chromosome 2 by 
analysis of Southern blots of DNA from a panel of human-rodent cell hybrids containing 
characteristic sets of human chromosomes (Kruse et al. 1988). In the same year the complete 
structure of primary human and rabbit lactase-phlorizin hydrolase translation products 
deduced from the cDNA sequences was reported (Mantei et al. 1988). Disappointingly in 
1991 Boll et al (Boll et al. 1991) showed that there were no sequence differences in any of 17 
exons of LPH gene, in exon-intron boundaries or in the 1 Kb region 5´of LPH gene, between 
lactase persistent and lactase non persistent subjects. They concluded that humans with high 
or low levels of lactase carry intact coding sequences of the LPH gene. In 1995 Wang et al 
(Wang et al. 1995) had shown that subjects heterozygous for the lactase persistence allele 
expressed one allele of the LPH transcript at much lower levels than the other allele and these 
subjects tend to have intermediate lactase activities. This finding supported the idea that the 
lactase persistence/non-persistence trait is likely to be controlled by cis-acting element(s) 
residing within or adjacent to the lactase gene rather than by a variation in a trans-acting 
factor (Wang et al. 1995). Thus, they suggested that expression of two LPH alleles could be 
independently regulated (Wang et al. 1995). In addition, further support has been observed by 
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strong linkage disequilibrium (LD) across the 70 kb haplotype spanning the lactase gene 
(Harvey et al. 1995). An interval of LD over 70 KB spanning the LPH gene has been 
observed in different populations with only 3 common haplotypes (Harvey et al. 1995; 
Harvey et al. 1998; Hollox et al. 2001).  One particular haplotype , called A, seemed to be 
associated with lactase persistence and was found at much higher frequencies in Northern 
European than any other populations (Harvey et al. 1998; Hollox et al. 2001). During these 
years a large number of single nucleotide polymorphism were found but none of them was 
shown to be the causative variant of lactase persistence (Boll et al. 1991; Lloyd et al. 1992; 
Harvey et al. 1995; Hollox et al. 1999). After studies by Boll et al (1991) no further sequence 
of the full length of the LPH gene has been reported before the present work. 
 
 
3.4 Mechanisms that underlie adult-type hypolactasia 
 
The mechanisms behind the timing of the onset of hypolactasia are poorly understood. Earlier 
studies have shown a wide ethnic and regional variation in the age of onset of adult-type 
hypolactasia. The majority of Thai children have shown to become hypolactasic by the age of 
two years, in black populations adult-type hypolactasia has been shown to manifest between 
one to eight years, whereas in white populations low lactase levels are rarely seen in children 
under five years of age (Keusch et al. 1969; Sahi et al. 1972; Welsh et al. 1978; Simoons 
1980). Wang et al (1995) studied the onset of lactase non persistence in children aged from 2 
months to 11 years. They analyzed subjects heterozygous for the lactase persistence using 
polymorphism within exons of the LPH gene as they did in previous study in adults, and 
monitored the asymmetric expression of the LPH transcripts, indicative for the down 
regulation of an allelic LPH transcription (Wang et al. 1998). Genetically programmed down-
regulation of the lactase gene was observed starting from the second year of life, although the 
extent and onset was not constant. They concluded that a developmentally regulated trans-
acting DNA-binding protein could bind to only one kind of lactase allele and influence 
transcription and/or mRNA stability (Wang et al. 1998). Previous studies of the Finnish 
population, based on lactose tolerance test, have shown that adult-type hypolactasia can 
manifest up to 20 years (Sahi et al. 1972). However, later recent data have shown that the 
majority of Finns have developed hypolactasia by age of 10 (Rasinpera H 2004). 
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4. Evolution of Lactase persistence  
 
Only little attention has been paid to the fact that is not quite appropriate to state that the 
prevalence of hypolactasia (instead of lactase persistence) varies considerable from less than 
5% to 100%, since this can be considered as the normal physiological condition of humans.  
Below I will present the prevalence data systematically for the abnormal state which is 
lactase persistence.  
 
Lactase persistence varies greatly between different and within populations from almost 0 % 
in South East Asia to 99 % in Northern Europe (Sahi 1994a). To explain these highly 
geographic variations in the prevalence of lactase persistence, various researchers have 
produced some hypotheses to explain these variations focused on some selective factors 
related to milk supply because it is the only source of lactose, the substrate of the lactase 
enzyme. These hypotheses are 
1) The culture historical hypothesis is based on genetic selection and correlates the 
occurrence of lactase persistence with dairy culture. This hypothesis is the most widely 
accepted and proposed by Simoons (Simoons 1969; Simoons 1970), later by McCracken 
(McCracken 1970) and refined by others (Johnson et al. 1974; Flatz and Rotthauwe 1977; 
Simoons 1978). It states that individuals with lactase persistence were able to use all the 
nutrients of milk, therefore, they were stronger, better equipped to survive and possibly had 
more children. Thus the proportion of people with lactase persistence would increase in a 
population. 
2) Calcium absorption hypothesis: This hypothesis was put forward to explain the prevalence 
of lactase persistence in Northern Europe (Flatz and Rotthauwe 1973). In this region of the 
world the nutritional supply of vitamin D was low and it was proposed that lactose could 
enhance absorption of calcium and thus individuals with lactase persistence will have less 
rickets and pelvic deformities resulting in a selection in favour of lactase persistence. Much 
criticism of this hypothesis been presented by Simoons (Simoons 2001) who have shown that 
lactase nonpersistence people can absorb calcium as lactase persistence people and this 
hypothesis is not confirmed by historical, osteoarachelogical or biomedical evidence.  
3) Selective advantage of lactase persistence to survive cholera and other epidemics have 
been proposed by Cook and Al Torki (Cook and al-Torki 1975). This hypothesis was put to 
explain the high frequency of lactase persistence in hot climates such as desert regions. 
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These three hypotheses were tested by comparative methods and most support was obtained 
for the historical culture hypothesis. Further, using maximum likelihood analysis it was 
shown that the evolution of milking seems to precede the evolution of lactase persistence 
(Holden and Mace 1997). Nowadays, there is a consensus that selection has been responsible 
for the high prevalence of lactase persistence. Haplotype analyses have suggest that much of 
the variation in the LPH locus has been affected by genetic drift with recent directional 
selection for lactase persistence (Hollox et al. 2001). The question remained then how much 
of the selection power was necessary to produce the observed frequencies in different 
populations. Some suggest that a selection power of 1% was sufficient to increase the gene 
from 5% to 60% in 10000 years, whereas others suggest a high selection power of 5-7% to 
explain the frequency in Northern Europe (Cavalli-Sforza 1973; Aoki 1986; Flatz 1987; Aoki 
2001).   
 
 
5. Lactase persistence/nonpersistence and human diseases  
 
5.1 Bone development and Osteoporosis 
 
The association of lactase non persistence and osteoporosis is one of the most common 
conditions studied so far. Lactase non persistence can be manifested clinically as lactose 
intolerance by abdominal bloating, cramping, distention, flatulence, and diarrhea, causing 
many people to avoid drinking milk, the main source of calcium (Birge et al. 1967). The role 
of calcium from milk and other dairy products has been shown to be essential for bone mass 
development. Therefore, lactose intolerance might lead to diminished calcium intake and 
reduced calcium absorption. Thus lactase non persistence has been considered to be a risk 
factor for osteoporosis and fractures (Birge et al. 1967; Newcomer et al. 1978; Finkenstedt et 
al. 1986; Horowitz et al. 1987; Mainguet et al. 1991; Wheadon et al. 1991; Corazza et al. 
1995; Di Stefano et al. 2001).  
 
However, there are conflicting reports whether the risk to osteoporosis is the result of lactase 
nonpersistence alone (Birge et al. 1967), or both lactase non persistence and lactose 
intolerance together (Finkenstedt et al. 1986; Horowitz et al. 1987; Mainguet et al. 1991; 
Slemenda et al. 1991). Two studies of Finnish perimenopausal women aged 38-57 years, 
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have shown that lactose intolerant women have a slightly reduced perimenopausal  bone 
mineran density (BMD) and elevated risk of fractures (Honkanen et al. 1996; Honkanen et al. 
1997). The main difficulty in studies addressing the impact of lactase nonpersistence on the 
osteoporosis and fracture risk in humans have been tedious and inaccurate diagnostic 
laboratory tests so far used for lactase non persistence.  
 
 
5.2 Diabetes Mellitus & other diseases 
 
In humans, intestinal lactase activity is increased in diabetes and been shown to be 
normalized with insulin treatment (Tandon et al. 1975; Mahmood et al. 1978; Schedl et al. 
1983; Murakami and Ikeda 1998). Furthermore, milk lipids, contain high amount of energy, 
might contribute to obesity and increased risk of diabetes. A high frequency of lactose 
absorbers (lactase persistence) was observed among diabetic type I and type II patients in 
Sardinia (Meloni et al. 2001). They studied 50 control subjects, 50 with diabetes type I, and 
50 with diabetes type II. They used breath hydrogen test and found 14% prevalence of lactase 
persistence compared to 48% in patient with type I diabetes, and 52% in patient with type II 
diabetes.  
 
Since people with lactase persistence supposedly drink more milk than people with lactase 
non persistence, high lactose consumption leads to a greater exposure to glucose and 
galactose. This might have implications for many other disease risks. Some support exist for 
a role of lactose ingestion and galactose cytotoxicity in the pathogenesis of ovarian cancer 
(Cramer 1989; Macdonald 1989; Mettlin and Piver 1990; Risch et al. 1994; Herrinton et al. 
1995; Webb et al. 1998; Meloni et al. 1999; Britton et al. 2000; Goodman et al. 2002), and in 
senile cataract (Simoons 1982; Bengtsson et al. 1984; Rinaldi et al. 1984; Spinelli et al. 1987; 
Lisker et al. 1988; Meloni et al. 1999). 
 
Considering ischemic heart disease ; it is thought that excessive intake of milk may result in 
abnormal serum profiles of triglycerides, and cholesterol increasing the risk for ischemic 
heart disease (Segall 1980; Segall 1994; Segall 2003). No correlation was found in males, and 
in females the sample size was not sufficient for statistical significant conclusions. In an 
Estonian study it was found that patients with acute myocardial infarction (MI) consumed 
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more milk than control persons (Lember and Tamm 1988). They found that the relative risk 
of MI for those who consumed 3 or more glasses of milk daily was 4 (95%CI 1.4-13.3) when 
compared to those who consumed less milk. It should emphasized that all the clinical 
correlations with lactase persistence/nonpersistence rather reflect the effect on milk drinking 
and since this habit has many determinants, beyond intestinal lactase activity, the results 
remain non- conclusive. 
 
 
6. Human genome Project (HGP) (1990-2003) 
 
6.1 Historical background, paving the way toward HGP 
 
The rules of heredity were established by Mendel, based on breeding experiments on pea 
plant and advanced by Sutton in his Chromosomal theory of heredity (Mendel 1866; Sutton 
1903). Hereditary transmission through the sperm and egg became known by 1860. It took  
20 years, in which the details of mitosis, meiosis and fertilization were clarified, to establish 
that the chromosomes were the active players in these processes (Olby 1966). 
 
Recognition the fact that DNA is the chemical hereditary material arose from studies of 
transformation of pneumonia causing bacteria (Griffith 1928; Avery 1944). Chargaff´s rules 
stated that nucleotide pairing A=T, and C=G in DNA and was based on the fact that the 
number of adenine residues was always equal to thymine and the number of cytosines equal 
to guanines (Chargaff 1949; Chargaff 1951). They showed that 3´-5´phosphodiester bonds 
regularly link the nucleotides of DNA. Then detailed analysis of high-quality photographs of 
X-ray diffraction pattern of DNA provided the basis for the correct determination of 
double helix structure for DNA by Watson and Crick. Structural studies greatly facilitated 
the understandings the details of  DNA replication was very soon recognized (Astbury 1951; 
Franklin and Gosling 1953; Watson and Crick 1953b; Watson and Crick 1953a). DNA 
synthesis in cell free extracts of bacteria with DNA polymerase I enzyme was demonstrated 
(Kornberg 1960) and the deciphering of the genetic code was finally interpreted (Nirenberg 
and Matthaei 1961; Cold Spring Harbor Publications 1966; Nirenberg 2004). The 
development of recombinant DNA technologies occurred in1970s (Jackson et al. 1972; 
Cohen et al. 1973; Lobban and Kaiser 1973). The concept that DNA molecule can be cut at 
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defined points by restriction enzymes (Smith and Wilcox 1970),  and again joined by DNA 
ligase enzyme (Lobban and Kaiser 1973), as well as the invention of powerful methods for 
DNA sequencing (Sanger and Coulson 1975; Maxam and Gilbert 1977; Smith et al. 1986), in 
vitro DNA amplification (polymerase chain reaction, PCR) (Saiki et al. 1988) set the stage 
for the official international Human genome Project to begin in 1990. 
 
 
6.2 Human genome project (HGP) 1990-2003 
 
The Human Genome project was officially launched in 1990 to create publicly accessible 
databases for high-quality sequences of genomes of human and key model organisms (human 
genome project information web site, 2004). The initial goals of HGP were to identify all 
genes in human DNA, determine the sequences of some 3 billion base pairs that make up 
human DNA, store this information in databases, improve tools for data analysis, transfer 
related technologies to the private sector, and address the ethical, legal, and social issues 
(ELSI) that may arise from the project. Although the project was initiated, and funded mainly 
by the US government, some 18 countries have participated in the worldwide effort, with 
significant contributions from the Sanger Center in the United Kingdom and genome centers 
in Germany, France, and Japan. Within the last decade, the program has rapidly progressed 
from the generation of genetic and physical maps, of chromosomes via the positioning of 
42000 ESTs (Deloukas et al. 1998) , to the production of a draft sequence of the human 
genome (Weissenbach et al. 1992; Cohen et al. 1993; Weissenbach 1993; Hudson et al. 1995; 
Dib et al. 1996; McPherson et al. 2001). The Human Genome Project reached its major goals 
in 2003 with the official completion of the human sequence on the 50th anniversary of 
Watson and Crick's description of the fundamental structure of DNA.  
 
  
The announcement of a private company Celera, in 1998, that it will finish the DNA 
sequence of human in a very rapid time frame using whole genome shotgun sequencing 
strategy (Venter et al. 1998), led the public efforts,  which relied on hierarchial sequencing 
strategy, to modify their goals and respond to the challenge. In June 2000, international 
leaders of the Human Genome Project (HGP) announced that the rough draft of the entire 
human genome would be completed a year ahead of schedule. Today this race is viewed as 
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beneficial for the scientific community and it resulted in the publication the first version of 
the human genome sequence in February 2001. The outcome of public effort was published 
in Nature (Lander et al. 2001) and that of Celera in Science (Venter et al. 2001). 
 
The ongoing analyses of the working draft have revealed interesting facts: The human 
genome contains 3164.7 million nucleotide bases and the average gene consists of 3000 
bases, the sizes varying greatly. The largest known human gene is dystrophin with 2.4 million 
bases. The total number of genes is estimated to be 22000, much lower than previous 
estimates of 80,000 to 140,000 that had been based on extrapolations from gene-rich areas of 
the genome (Cold Spring Harbor Genome meeting 2004, www.cshl.edu). Less than 2% of the 
genome sequence encodes for proteins. Repeated sequences, not coding for proteins make up 
at least 50% of the sequence. The human genome has a much greater portion (50%) of repeat 
sequences than the mustard weed (11%), the worm (7%), and the fly (3%)(Lander et al. 2001; 
Venter et al. 2001) (Human genome project information web site, 2004). Chromosome 1 has 
highest number of genes (2968), and the Y chromosome the lowest (231).  
 
In addition to the human DNA sequence, the HGP also aimed to sequence the genomes of 
model organisms, which serve as outstanding tools for the identification of the genes and 
their regulatory elements as well as the functional protein domains. Comparative genomics 
provides a key informational tool for understanding the functions of human genome as well 
as defects resulting in human diseases. For example, approximately 80% of the 30000 human 
genes seem to have one single identifiable ortholog in the mouse genome, whereas the 
proportions of human genes without any detected homologous in the mouse is less than 1% 
(Waterston et al. 2002). To date, the genomes of numerous model organisms have been 
sequenced (NCBI and NHGRI web pages) including the completed genome sequences of 
E. coli (Pennisi 1997), S. cerevisiae (Goffeau et al. 1996), C. elegans (1998), 
D. melanogaster (Adams et al. 2000), as well as whole-genome drafts of species like C. 
briggsae, D. pseudoobscura, mouse (Mus musculus) (Waterston et al. 2002), and rat (Rattus 
Norvigicus) (Gibbs et al. 2004). In addition, sequence efforts are on the way for genomes of  
other mammalians like the oow (Bos taurus), Pig (Sus scrofa), and Dog (boxer breeder). 
Information of these genomes will add profoundly to our understanding of the evolutionary 
processes of the last 100 million years, and will greatly facilitate identification of diseases 
genes. 
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6.3 Beyond the HGP in the 21st century 
 
The analytical power arising from the reference DNA sequences of entire genomes provides 
to an era that has been predicted to be the century of biology. One of the greatest impacts of 
having the genome sequences available lie in our entirely new possibilities in biological 
research. We have entered the genomic era and the potential of the HGP could be used to 
improve human health and well-being and fighting disease (Collins et al. 2003). The HGP set 
the challenges for the future to understand the geography and function of the genome (DNA 
sequence organization, chromosomal structure and organization, noncoding DNA types; 
amount; distribution; information content; and functions) and opened avenues to research 
problems which could not be addressed before: precise gene number and function, gene 
regulation, the spatiotemporal expression pattern of the human genes, novel metabolic 
pathways and protein interactions. We can develop genome-based approaches for disease 
diagnostics and for predictions of normal biological features like individual drug response. 
These explorations will result in a more comprehensive view to human biology and provide 
us with profound understanding of these complex systems. 
 
 
6.4 Genetic Diversity in Humans, HapMap project 
 
Even though the human genome sequence exists, detailed characterization of the heritable 
variation in the human genome is needed to increase our understanding of traits and diseases, 
many of them involving the interplay between multiple genetic and environmental factors 
(Daly et al. 2001; Peltonen and McKusick 2001; Gabriel et al. 2002; Bersaglieri et al. 2004). 
The DNA sequence of any two people is 99.9 percent identical, but the remaining 0.1% is 
important since it contains the genetic variants that influence how people differ in their risk 
of disease or their response to drugs. Sites in the DNA sequence where individuals differ at a 
single DNA base are called single nucleotide polymorphisms (SNPs). Sets of nearby SNPs 
on the same chromosome are inherited in blocks. This pattern of SNPs on a block is a 
haplotype. Blocks may contain a large number of SNPs, but a few SNPs are enough to 
uniquely identify the haplotypes in a block. A map of these haplotype blocks and the specific 
SNPs that identify the haplotypes are called tag SNPs will constitute what is known The 
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HapMap which will describe the common patterns of human DNA sequence variation 
(Johnson et al. 2001; 2003). This will make genome scan approaches to finding regions with 
genes that affect diseases much more efficient and comprehensive by reducing the number of 
SNPs required to examine. The haplotype map, or "HapMap," is hoped to provide the 
scientific community with a tool that will allow researchers to find genes (Van Den Oord and 
Neale 2003) and genetic variations that affect: health and disease, response to environmental 
factors, susceptibility to infection, and the effectiveness of and adverse responses to drugs 
and vaccines (Cardon and Abecasis 2003; Deloukas and Bentley 2004), (www.hapmap.org). 
 
 
7. Identification of disease genes 
 
7.1 Principles and Strategies 
 
A few areas of biological research have progressed as fast as human disease gene 
identification. The choice of strategy depends on what resources are available for the study 
(family material, cases control, funding ...etc), and how much is known about the 
pathogenesis of the disease. In summary the disease gene identification studies involve two 
steps: 
1) Initial disease gene identification 
2) Verification of the causative role and the population attributable fraction of the identified 
variants 
Disease gene identification can be performed via functional or positional cloning. 
When some information exits about the metabolic disturbance behind the disease, this 
information can be used to identify the mutated gene. Information of the suspect gene 
products (proteins) can be used to produce gene specific oligonucleotides or raising specific 
antibodies for screening cDNA libraries to identify clones encoding the genetic elements of 
interest.  
 In positional cloning the disease gene is isolated based on its chromosomal mapping 
location. Generally this includes two approaches:  
a) Position-independent candidate gene approach: if the phenotype of the disease 
resembles another phenotype in animals or humans for which the gene is known, or if 
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pathogenesis suggests that the gene may be a member of a known gene family, then we 
sequence that gene directly without knowing the chromosomal location. This approach has 
only rarely been successful.       
b) Positional dependent approach: involves the following steps 
1. Identification of the chromosomal region 
       i)  Via genome-wide genotyping and linkage analysis: the most common approach 
used for mapping Mendelian disorders. 
       ii) Via identification of chromosomal abnormalities:  chromosomal staining can 
implicate the missing or excessive region. 
       iii) Via comparative hybridization and/or Loss of heterozygosity screening: 
commonly used in tumor genes due to common deletion reported in tumors. 
 2. Physical mapping: This step is getting less and less demanding, thanks to the HGP. Once 
you mapped the locus, you just go to the databases, find the physical map and the complete 
sequence of the region you need to analyze for mutations (www.ncbi.nih.gov). 
  3. Fine mapping: by using Linkage disequilibrium (LD), haplotype sharing, usually the 
linkage analysis maps the region to few cM, which is still considered too large for sequence 
analyses. In order to restrict the disease locus to small region, one can, especially in founder 
populations use LD and/or allelic association, and haplotype sharing for fine mapping of the 
locus. 
 4. Selection of candidate gene in the restricted region: Even after fine mapping the 
disease locus the region typically remains too large and contains tens of genes.  It is useful to 
collect all information guide to the most probable candidate genes; This approach called 
positional candidate gene approach.  
This includes looking for genes which show appropriate expression pattern and for function 
of the genes in the region, or homology to a relevant gene or ESTs in human or model 
organisms. Sometimes, the restricted region seem not to harbor any known gene, and one has 
to use computational methods for gene identification, a process known as cloning in silico. 
There are many computer software tools for the analysis of genomic sequence which have 
been developed to predict gene structure like GeneID (Guigo et al. 1992) and Genescan 
(Burge and Karlin 1997) , or only exon prediction programs like MZEF (Zhang 1997) and 
Grail II (Xu et al. 1994). Although the accuracy of the prediction programs range between 
80-90 % (Burge and Karlin 1997; Zhang 1997), the approach is less time consuming than non 
computational methods like Zoo-blottin (Claudio et al. 1994), CpG island identification 
(Antequera and Bird 1993), hybridization to mRNA/cDNA (Northern blot), exon trapping 
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(artificial RNA splicing assay) (Church et al. 1994), or cDNA selection/capture (Lovett 
1994) methods used for identification of genes in a restricted chromosomal region.  
 
5. Testing candidate genes 
Ultimately, individual candidate genes have to be tested individually to see if there is 
compelling evidence that mutations in them do cause the disease in question. This can be 
performed by various means: 
I) Mutation screening: screening for patient-specific DNA-variants is the most immediate 
task. If the correct gene is tested, identifying mutations in several unrelated patients; 
including some with an obvious deleterious effect; and absence of the variant from the 
control samples strongly suggests a causative role. 
II) Confirmation of the mutation: Formal proof that mutation is indeed the causative one 
requires additional evidence. This can be conducted by Restoration of normal phenotype in 
vitro by transfection of a cloned normal allele into a model cell line carrying the disease 
phenotype can provide evidence that that gene is associated with the disease or production of 
a mouse model of the disease to show some resemblance to humans with the disease, 
although this may not always be the case even if the correct gene has been identified due to 
differences between human and mouse biology. 
In some other circumstances the confirmation of mutations and the interpretation of mutation 
screening can be difficult due to several reasons including: Unsuspected locus heterogeneity ( 
mutations in the candidate gene account only for a small proportion of the cases tested),  
Mutations are not ambiguously pathogenic (difficult to distinguish pathogenic missense 
mutations from neutral variants), Mutations may be hard to find ; this may be due to the large 
size of the candidate gene, or to difficulties in detecting mutations using the standard PCR 
methods (e.g. mutations in the F8C gene causing severe hemophilia A were initially hard to 
find because many were large inversions which disrupted the gene) (Strachan 1999). 
Most disease genes that have been identified by a positional candidate strategy represent 
Mendelian monogeneic rare disorders. However, in complex disorders or common 
disorders positional cloning is not an easy way to identify susceptibility genes due to locus 
heterogeneity, low penetrance and differences between the populations. In most cases no 
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single susceptibility gene will be mutated in every patient with the disease. However, today’s 
sequence information on the web has moved disease gene identification from the map-based 
gene discovery to sequence-based gene discovery. Precise transcript maps, identification of 
millions of SNP-variants combined with novel biostatistical strategies will facilitate 
monitoring of “genome-wide risk profiles” and hopefully expose genetic variants which also 
predispose individuals to common diseases 
 
 
7.3 Linkage analysis in disease gene mapping 
 
The aim of genetic mapping is to assign a disease locus to a specific chromosomal region by 
the use of the genome-wide marker set and linkage analyses. Linkage analysis (typically in 
families) calculate how often two loci (a marker and unknown disease locus) are separated by 
meiotic recombination through monitoring the co-segregation of alleles in subjects from 
families with trait under investigation.  
In the early days the first genetic markers used were restriction fragment length 
polymorphism (RFLP) (Botstein et al. 1980), tediously identifiable with restriction 
enzymes, in the PCR era, a switch to use short tandem repeats (STR), also known as 
microsatellites has taken place. STR has numerous advantages over RFLPs; they are highly 
informative, easy to type, and even dispersed throughout the genome. STR usually consists of 
10-50 copies of di, tri, tetra, or pentanucleotides repeats. The most common repeats (CA)n  
are distributed evenly at 30-50 kb intervals in the human genome. 
 
The principle of linkage analysis is based on fact that for any two loci on the same 
chromosome the chance of cross over event between them (recombination) during the 
meiosis depends on distance between them. The closer two loci are to each other, the smaller 
is the chance for recombination between them. The measure of genetic linkage is the 
recombination fraction, theta (0⊆ Θ ⊆0.5), which is a measure of the distance between two 
loci defined by the frequency at which a cross over event took place in the observed number 
of meiotic events. An estimate of Θ = 0.5 is consistent with the two loci being unlinked (this 
can be considered as two loci on different chromosomes, or located more than 50 cM on the 
same chromosome). It can be performed in a parametric manner (when mode of inheritance is 
known, other parameters can be justified, as the case in Mendelian disorders) or 
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nonparametric (when the mode of inheritance is not known, or the trait does not obey 
Mendelian rules like in complex disorders). In Mendelian monogenic diseases tests of linkage 
are mostly based on maximum likelihood estimation and likelihood ratio testing, also called 
parametric lod score analysis. In linkage analysis the overall likelihood of the data on two 
alternative assumption is calculated in which the likelihood (L) that two loci (i.e. marker and 
disease locus) are linked with recombination fraction (Θ) is compared to the likelihood that 
they are not linked (Θ=0.5). The logarithm to the base 10 (log10) of the ratio of these two 
likelihoods is what is called the lod score (Z) (Morton 1955).  
10
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The most likely distance between two loci (e.g. marker and a disease locus) is the 
recombination fraction (Θ) at which the two point lod score peaks. Traditionally, an odd ratio 
of more than 1000:1 in favour of linkage (expressed on a logarithmic scale as LOD score of 
3) is considered a statistically significant demonstration of linkage. An odd ratio of < 1:100 
(LOD score <-2) is agreed to demonstrate the exclusion of linkage (a 100 times likely not to 
be linked) (Morton 1955; Ott 1999). To extract more information about a region, a multipoint 
lod score analysis, using the information of adjacent marker loci. 
 
Computer based program packages have been developed to facilitate the calculation of 
linkage such as LINKAGE (Lathrop and Lalouel 1984; Lathrop et al. 1984).  
The main disadvantage of parametric linkage analysis is the dependence on the estimates for 
mode of inheritance, penetrance, and gene frequency- parameters usually well enough 
characterized for a single gene disorders but not in complex disorders (Goring and 
Terwilliger 2000a; Terwilliger and Goring 2000). Model free nonparametric methods like 
Affected Sibpair analysis (ASP), homozygosity mapping, and association analysis have been 
used for complex disorders to circumvent some of the problems. There are many computer 
programs have been developed to carry out these analyses. These programs include 
GENEHUNTER (Kruglyak et al. 1996), MAPMAKER/SIBS (Kruglyak and Lander 1995), 
and SIMWALK (Sobel and Lange 1996). 
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7.4 Linkage disequilibrium  
 
Linkage disequilibrium (LD), is defined as the non random association of alleles of linked 
markers (Terwilliger et al. 1998). LD can arise from a variety of causes including: recent 
mutation, population founder effects, recent admixture of populations with different allele 
frequencies, selection in favour of a specific allele, and demographic history of a population 
(Slatkin 1994; Laan and Paabo 1997). Several factors influence the level of observed LD, 
such as the chromosomal region under study, the age and mutual distance of the markers 
(properties of the markers), the age and the history of the population (genetic drift, population 
growth and structure, admixture or migration) and selection (Ardlie et al. 2002; Nemeth et al. 
2003). LD is disrupted by recombination, mutation, and conversion events. Average LD 
declines with distance, but there is large variation between different chromosomal regions. 
Figure 4 graphically presents the principle used for LD mapping. 
 
Five different measures have been used for LD (Guo 1997). The correlation coefficient ∆, 
Lewontin´s D´, the robust formulation of the population attributable risk δ, and Kaplan and 
Weir's proportional difference d. They show that under complete LD between marker and 
disease locus and of no mutation at the marker or the disease locus, δ is the best measure for 
fine mapping purposes, and D´ is equally best in many realistic settings (Devlin and Risch 
1995). The statistical significance can be measured by traditional chi-square (χ2) test, Fisher's 
exact test and the likelihood based lambda (λ) test (Terwilliger 1995). In simulation studies 
they show that the performance of all measures depends on the marker allele frequency and 
initial incomplete LD could render all measures useless (Guo 1997). 
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Figure 4. The Principle of linkage disequilibrium (LD) mapping. The conserved region flanking the disease mutation, 
diminish after generations due to recombination events. In the course of time, only a short chromosomal segment is preserved 
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be in LD with disease mutation after long time. The same principle can be used in a similar manner in Haplotype analyses 
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LD is proven to be a powerful method for the high resolution mapping of monogenic 
disorders (Hastbacka et al. 1994; Peltonen et al. 1999). LD and haplotype sharing strategies 
have provided short cuts to disease gene identification in isolates (Peltonen et al. 2000). The 
length of LD interval along the disease allele can be utilized to estimate the age of mutations 
(Varilo 1999). The younger the mutation the more extended is the observable region of LD 
flanking the disease mutation. This can be seen clearly in the mapping studies of mutations 
behind Finnish disease heritage (Varilo et al. 1996b; Peltonen et al. 1999).  
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AIMS OF THE PRESENT STUDY 
 
This study was initiated when no family studies using molecular genetics methods of human 
lactase deficiencies had been preformed and the genetic loci were unknown and no detailed 
genetic characterization for the lactase persistence/non persistence variant had been 
conducted.  
 
The main aim of this work was: 
      1. To position the locus for the congenital lactase deficiency 
      2. To identify the molecular variant behind the adult lactase persistence and to address 
          the functional role of the DNA-variant. 
      3. To study the prevalence of DNA-variant and to analyze the allelic diversity of  
           lactase persistence locus in global populations  
      4. To address the potential relationship between lactase persistence and diabetes type I  
           and type II in the Finnish population  
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MATERIALS AND METHODS 
 
1. Study materials 
 
1.1 The samples analyzed in different studies 
 
In total, more than 5000 samples, collected by our clinical collaborators have been analyzed 
in this project:  
 
I) Congenital lactase deficiency study (CLD) (Study I): 
 
A total of 91 DNA samples comprising of 27 CLD patients belonging into 19 families and 64 
healthy family members were enrolled in the linkage study for CLD project. The pedigrees 
for the 19 families shown into (Figure 1, study I). The diagnosis of all patients was based on 
clinical symptoms in addition an estimation of lactase activity in a jejunal biopsy specimen 
was performed for all but one patient as described (Savilahti et al. 1983). In addition, in the 
genealogical study information from 31 families were traced for 3 generations of ancestors on 
the basis of local church registries (Varilo et al. 1996a).  
 
II) Lactase nonpersistence/persistence studies (studies II, III, IV, V) 
 
a- A total of 145 individual tested by LTTE, from nine extended Finnish pedigrees originally 
studied by Timo sahi in 1970s for adult-type hypolactasia were enrolled in the linkage study 
for adult-type hypolactasia. We also enlarged this family study by collecting the DNA 
samples (19 samples) from family members in the younger generations (Figure 1, study II). 
In total 194 individual >20 years at time of testing were enrolled in the linkage study, in 
which 90 DNA samples were available for the study. 
 
b- 1037 DNA random samples, collected from Finland, Utah, France, African Americans, 
Italy, and South Korea were included in the epidemiological study of adult-type hypolactasia 
(study II).  
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c- 250 intestinal biopsy sample specimens ascertained for disaccharidase activities were 
tested for any correlation between the genetic variants identified and adult-type hypolactasia 
(study II and unpublished data). 
d- A total of 52 intestinal biopsy specimens from an independent set of 52 patients with 
abdominal complaints were collected prospectively to study relationship between the LPH 
mRNA and C/T-13910 and G/A-22018 polymorphisms associated with lactase persistence (Study 
III).     
e- A total of 1455 patients with type 1 and 615 with type 2 diabetes in addition to 446 non-
diabetic subjects from Western Finland have been studied for the relationship between lactase 
persistence and diabetes (study IV).  
f- A total of 1611 samples from 37 populations of 11 different global regions were collected 
for the study addressing the age and the origin of lactase persistence mutation (study V) 
Table 2.  
g- In addition, 122 anonymous Finnish families with both parents and one child were 
analyzed for LD and haplotype block analyses of the LPH locus (study V).  
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Table 2. The population samples analyzed in the study V. 
Region  Population   Population groups 
A. East Asia: South Korea
 Han Chinese
B. Trans-Urals:  
  I. East Urals:  Ob-Ugric speakers
  
  II. West Urals: Komi 
 Udmurts
 Mokshas
 Erzas 
 Saami
 Finns-East region
 Finns-West region
C-Caucasus: Dahgestan: Druss 
  Nog 
  Mixed 
D-West Asia: Pakistan: Somi Balti 
  Burusho 
  Kashmiri 
  Kalash 
  Pathan 
  Hazara 
  Bal balcuh 
  Sindi 
  Brahui 
  M.Baluch 
  Mohanna 
  Parsi 
 Iran: Iraninans 
  Nomad Iranians 
 Arabians
E-West Mediterreans:  South Italians
  France (part of CEPH)
  Basques
F-North America: Utah (CEPH collection)
G-East Africa: Somalians
H-Sub Sahara Africa: Fulani-Sudanese
I-North Africa: Saharawi
 Morrocans
J-African-Americans  
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1.2 Assay of Intestinal disacchridases 
 
The assay of intestinal disacchridases is based on the fact that the activity of the intestinal 
disacchridase studied correlates directly to the amount of glucose liberated when the 
intestinal mucosal preparations are incubated with the respective substrate disacchrides. The 
assay is carried out using Tris-glucose oxidase (TGO) reagent (Dahlqvist 1964; Messer and 
Dahlqvist 1966). Lactase, maltase and sucrase activities were determined according to the 
method of Dahlqvist (Dahlqvist 1964). The assay is carried out as follow: first, the intestinal 
biopsies were weighted, solubilized in cold NaCI (100 ul/mg tissue) and homogenized on ice 
for 45 seconds and centrifuged for 15 min (4500 rpm). Second, supernatants diluted in cold 
NaCI, pipetted on a Deep Well plate, mixed by vortexing and incubated at 37 ºC for 60 
minutes. After that 300 ul of ice cold glucose oxidase (GO) reagent was added to each well 
and incubated again in 37 ºC for 60 minutes. Third, the absorbance of the samples was 
measured at the wavelength of 450 nm on a Multiscan spectrophotometer and the activity of 
the diasacchridases calculated as units of enzyme activity (U). One unit is defined as the 
activity of a disacchridase needed to hydrolyze 1 umol of dissachride per minute. 
 
Lactase deficiency was diagnosed when the activity of lactase was below 20U/g protein and 
lactase/sucrase ratio <0.3. Activities of maltase and sucrase were determined in order to 
exclude patients with secondary lactase deficiency. Low activities of all disaccharidase 
enzymes are seen when mucosa is injured, in cases such as celiac disease or inflammation, or 
if the biopsy sample is obtained from a too proximal part of the intestine (Kolho and Savilahti 
2000). 
 
 
1.3 Lactose Tolerance Test with ethanol (LTTE) 
 
LTTE was performed in the families included in the adult-type hypolactasia study. Simple 
LTTE was conducted because it is more reliable than LTT (Sahi et al. 1973; Sahi 1974a; Sahi 
1974b). After overnight fasting the patients were given 0.3 g/Kg of ethanol by mouth to 
inhibit galactose metabolism in the liver (Tygstrup and Lundquist 1962) and 15 minutes later 
50 g lactose was given as a 12.5% solution. Capillary blood samples were taken before, 20 
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minutes and after 40 minutes after the lactose for determination of blood glucose and 
galactose concentration by the glucose oxidase and galactose oxidase methods. 
 
The results of LTTE were expressed as a maximum rise in the blood glucose and galactose 
concentration in mg/100 ml above the fasting level. The criteria for hypolactasia were: 
a) a maximum rise in blood glucose < 20mg/100 ml and   
b) a maximum rise in blood galactose < 5 mg/100 ml.  
If the subject fulfilled both criteria, a glucose-galactose tolerance test with ethanol was 
performed to exclude general malabsorption and the possibility of secondary hypolactasia. 
They were given 25 g glucose + 25 g galactose in the same amount of water as lactose in 
LTTE. If minimum rise was at least >20 mg/100 ml for glucose, 5 mg/100 ml for galactose, 
the secondary cause can be excluded. If one of the sugars shows absorption below the limit 
then the subject was sent for a small intestinal biopsy and histological examination to 
determine the disaccharidase activities. 
 
 
1.4 DNA extraction 
 
Genomic DNA was extracted from frozen peripheral blood, in accordance with standard 
protocols (Vandenplas et al. 1984). In addition, DNA was isolated from intestinal biopsy 
specimens after assaying dissachridase activities. The samples were moved into a proteinase-
K buffer (0.5 % SDS, 0.1 M NaCI, 50 mM Tris pH 8.1, 20mM EDTA) and proteinase K (20 
mg/ml) was added in order to dissolve the proteins. After an overnight incubation in 37ºC the 
DNA was extracted by phenol-chloroform extraction (Sambrook 1989). Precipitation of DNA 
was done in - 70 ºC for 15 min after addition of 2.5 vol cold ethanol and 1/10 vol 3 M NaAc. 
Finally the samples were centrifuged, washed with 70% ethanol, lyophilized and solubilized 
in 50 µl dH2O. 
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2. DNA analysis 
 
2.1 Genotyping 
 
For genotyping in study I, a total of 10 polymorphic microsatellite markers on chromosome 2 
q (Dib et al. 1996) were amplified by PCR using 32P- γ ATP- labelled primers in PCR 
(Sambrook 1989). The order of markers was obtained mostly from the physical YAC contig 
map of chromosome 2 (Chumakov et al. 1995), supplemented with data from the Généthon 
map (Dib et al. 1996). In study II, a total of 16 microsatellite markers within the contig 
constructed over the LPH region were identified from the published genomic sequence of the 
BACs (NH034L23, NH0318L13, and RP11-329I) using the repeat Masker program were 
amplified by PCR using 32P- γ ATP- labelled primers in PCR. PCR was performed in a total 
volume of 15 ul containing 12 ng template DNA, 5 pmol of the primers, 0.2 mM of each 
nucleotide, 20 mM TrisHCI (pH 8.8), 15mM (NH4)SO4, 1.5 mM MgCI2, 0.1% Tween 20, 
0.01% gelatine, and 0.25 U Taq polymerase (Dynazyme, Finnzymes). The PCR was carried 
on for 35 cycles, initial denaturation for 3 min then denaturation at 94ºC for 30 s, annealing 
at various temperatures depending on the perimers, for 30 s, and extension at 72ºC for 30 s; 
and final extension for 5 min. The amplified PRC fragments were separated on 6% 
polyacrylamide gels, and autoradiography was performed. 
 
SNPs of LPH region were analyzed using either minisequencing (Syvanen et al. 1993) (SNPs 
13-21), or (SNPs1-11, 23-29) using the primer extension on the chip (Pastinen et al. 2000). In 
addition, 3.5 kb deletion/insertion (del/Ins) polymorphism within intron one of the LPH gene 
was genotyped by analysis of PCR product on 1.5% agarose gel. PCR for the del/Ins was 
designed using 3 primers in the reaction which give to one band 900 bp for the insertion 
allele and 600 bp for the deleted allele.  
 
A total of 8 SNPs and one del/ins polymorphism were genotyped in 37 populations. The 
DNA fragments spanning the analyzed SNPs were amplified using a biotinylated (4-10 ng), 
and an unbiotinylated primer (20 ng), in a 50 ul volume with genomic DNA (100ng), dNTP 
(200uM), 0.5 U of Taq polymerase (Dynazyme, Finnzymes) in a standard buffer. The PCR 
procedure was carried out as reported before (Figure 5).  
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Figure 5 . (a) Map of the 24 SNP sites and one deletion-insertion. Number of kb from the first ATG of LPH is shown. (b) 
Genes in the region studied. (c) Expanded map of the LPH and MCM6 region. 
 
2.2 Sequence and mutation analysis 
 
The draft genomic sequence of the BACs: NH0034L23, NH0218L22 NH0318L23, and RP-
329I10 that covered the critical region of adult-type hypolactasia were assembled to one 
contig using Sequencher 4 software (Gene Codes Corporation). Oligonucleotide primers 
spanning the critical region between markers D2S3013 and D2S3014 were designed and PCR 
amplifications were carried out in a 50 µl volume with genomic DNA (100 ng), primers (20 
ng each), dNTPs (200 µM), 0.5 U of Taq polymerase (Dynazyme, Finnzymes) in a standard 
buffer. Most PCR were amplified using the following PCR cycle conditions: an initial round 
of denaturation at 94 0C for 3 min, then 35 cycle at 940C at 30 s, 55 0C for 30 s, and 72 0C for 
1.25 min and a final extension of 72 0C for 10 min, except that in cases where the size of the 
PCR products were more than 1kb when we used the Dynazyme extend kit.  
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Purified PCR products (15-40 ng) were cycle sequenced using BigDye terminator chemistry 
(PE Biosystems). Data were analyzed using ABI Sequencing Analysis 3.3 (PE Biosystems) 
and Sequencher 4.1 (Gene Codes). 
 
 
2.3 Solid-Phase Minisequencing       
 
The DNA fragment spanning SNPs analyzed was amplified using a biotinylated and an 
unbiotinylated primer (study II, III, IV and V). An aliquot (10) µl of the PCR product was 
captured in a streptavidin coated microtitre well (Labsystems, Finland). The wells were 
washed, and the bound DNA was denatured as described previously (Syvanen et al. 1993). 
Typically, 50 µl of the minisequencing reaction mixture contained 10 pmoles of the 
minisequencing primers for each SNP and 0.1 µl of either 3H-dNTP corresponding to the first 
and second allele of each SNP (Amersham, UK), and 0.05 units of DNA polymerase 
(Dynazyme II, Finnzymes). The microtiter plates were incubated for 20 min at 50 ºC, and the 
wells were washed. The detection primer was eluted, and the eluted radioactivity was 
measured using scintillation counter (1450 Microbeta; Perkin Elmer). Two parallel 
minisequencing reactions were carried out for each PCR product. The ratio (R) between the 
incorporated labels was calculated by the equation: R= count per minute (cpm) detecting 
nucleotide associated with persistent allele/ cpm detecting nucleotide associated non 
persistent allele.  
 
 
2.4 RH mapping        
 
A high resolution whole genome (TNG) RH panel (Research Genetics) comprising 90 
human-hamster hybrid lines was analyzed together with a human lymphoblastoid cell line 
(RM; positive control) and non irradiated hamster recipient cells (A3; negative control). The 
markers were amplified, by PCR, from each RH well. PCRs were performed with 15 ng 
template, 60 pmol of the primers, 200 uM each dNTP, and 0.5 U Tag polymerase 
(Dynazyme, Finnzymes) in 50 ul buffer under the condition described above. The PCR 
products were visualized on 1.5% agarose gels. The screening results for the TNG panel were 
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analyzed by use of the RH server at SHGC, and the RHMAP statistical package for RH 
mapping (Cox et al. 1990; Boehnke et al. 1991; Olivier et al. 2001).  
 
 
2.5 Physical mapping 
 
2.5.1 For CLD locus 
 
At the time when we begun the project a considerable time was needed in constructing a 
physical map over the CLD region. The initial YAC contigs were assembled by 
CEPH/Généthon. YAC clones previously assigned to chromosomes 2q were ordered from the 
Sanger Centre (Medical Research Council, United Kingdom). The presence of the known 
markers of the CLD locus and three primers pairs designed from exon 1, 8, and 17 (SHGC-
10723) of the LPH cDNA (Mantei et al. 1988) were tested by PCR. Similarly, a P1-derived 
artificial chromosome (PAC) library on 321 multiwell microtitration plates (Kindly provided 
by Prof. Peter de Jong, Roswell Park Cancer Institute)(Ioannou et al. 1994) was screened for 
the presence of the LPH gene and 5 closest markers. The PCR positive clones were picked up 
and cultured  in Luria broth supplemented with 25 ug kanamycin/ml, and DNA was extracted 
from these cultures, in accordance with the standard alkaline-lysis method (Sambrook 1989). 
The PCR conditions were similar to those used in family studies. 
 
 
2.5.2 For adult-type hypolactasia locus 
 
The draft sequence of the BACs over the LPH region was published in 1999. These published 
sequences were screened with the known markers and other new markers in the region using 
Repeat Masker program and Sequencher 4 soft ware (GeneCodes) (Figure 2, study II). 
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3. Linkage and LD analyses 
 
Pairwise LOD scores were calculated by use of the MLINK option of the LINKAGE program 
package (Lathrop and Lalouel 1984). An autosomal recessive mode of inheritance (Savilahti 
et al. 1983) for CLD with compete penetrance and disease allele frequency of 0.001 was 
assumed. LD analysis were performed by using the program HRRLAMB (Terwilliger 1995). 
This program applies a likelihood-ratio test for LD, calculated as parameter λ, that is 
independent of the number of alleles and, by extension, of the number of marker loci over a 
small chromosomal region. In addition, all genotyping data were analyzed using the 
HRRMULT program, which is designed for joint analysis of multiple loci. In this method, the 
recombination fraction between any given map position and each of the marker loci is fixed, 
and the likelihood is maximized, at that map position, over α (proportion of disease originally 
associated with a certain allele) and n (number of generations since introduction of the 
founder disease allele into the population). 
 
For adult-type hypolactasia pairwise LOD scores were calculated using the MLINK option of 
the LINKAGE program package (Lathrop and Lalouel 1984). Autosomal recessive 
inheritance with complete penetrance, no sex difference in recombination fractions, and a 
disease allele frequency of 0.4 was assumed. Only individuals above 20 years of age were 
included in the study as the condition is manifested by that age in the Finnish population 
(Sahi et al. 1973; Sahi 1994a). The affection status for individuals not confirmed by LTTE 
was regarded as unknown. Allele frequencies and heterozygosity for the markers were 
estimated from family material using the Downfreq program for purposes of the parametric 
linkage analysis (Goring and Terwilliger 2000b). Additionally, a pseudomarker linkage and 
linkage disequilibrium analyses were performed, assuming autosomal recessive mode of 
inheritance (Goring and Terwilliger 2000c). A test of LD was performed conditional on the 
detected linkage treating the allele frequencies and the recombination fraction as nuisance 
parameters (Goring and Terwilliger 2000b; Goring and Terwilliger 2000c). 
 
Pairwise LD between C/T-13910 and G/A-22018 in 1037 Samples was estimated using the D‘ 
statistic (Thompson et al. 1988). Haplotype frequencies were estimated by maximum likelihood 
using the EH program (Terwilliger 1994). D` is calculated as max (D/ Dmax, D/Dmin) :  where the 
disequilibrium measure D = hpq— p q, where hpq is the frequency of the haplotype with rare 
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allele at each locus, p and q are frequencies of the rare alleles at loci 1 and 2 , and  Dmax = min 
p(1-p),q(1-q) if D>0, and Dmin = -min pq, (1-p)(1-q) if D<0. The significance of deviation of D´ 
from 0 was determined using the statistic D2 
)1()1( qqpp
N
−−
 which is distributed as χ2 with 1 
df (Thompson et al. 1988) .  
 
LD statistics were calculated in 122 Finnish trio families using Genepop program version 3.4, 
in which contingency tables were constructed to test for genotypic (in population samples) or 
gametic (for the haploid case) linkage disequilibrium for all pairs of loci in each sample. For 
each locus pair within each sample, the unbiased estimate of the P-value as well as the 
standard error was estimated. Then, a global test (Fisher's method) for each pair of loci was 
performed across samples. The results of LD analysis were then depicted using GOLD 
program (Abecasis and Cookson 2000). MDLBlockFinder (Koivisto et al. 2003) was used to 
predict the haplotype block structure underlying the region and assess the probability of a 
block boundary between each pair of adjacent markers.  
 
 
3.1 Estimation the age of lactase persistent mutation using LD 
 
The analyses were carried out using algorithm of Risch et al (Risch et al. 1995), without and 
with Luria-Delbrűck correction of the genetic clock (Labuda et al. 1996), respectively: g=log 
δ/log (1-Θ) and gc=g+go, where go=-(1/d) In (Θxfd), assuming d=0.085 (mean population 
growth rate) (Hastbacka et al. 1992) and fd= 1/d . The estimate is based on the observation, in 
33 lactase persistence-bearing and 52 non-persistence-bearing chromosomes, of the 
frequency of the allele 2 of the marker D2S3014, which showed the highest LD with the trait 
in the family study.  The LD measure (δ) was calculated as follow, δ= (Pper - Pnon-per)/(1- Pnon-
per) in which Pper and Pnon-per are the frequencies for the marker allele on persistence bearing 
and non-persistence bearing chromosomes in the Finnish families, respectively (Bengtsson 
and Thomson 1981). The variance of (δ) was approximated by 
Var (δ)= ( ) 222224 )1()1()1( 1 pnonpperpnon pperpperpnon −+−+− σσσ . 
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An approximation of the confidence interval of δ was then obtained as δ±1.96σδ, where 
σ2δ=Var (δ).  Three conversion Factors for the genetic distance (recombination fraction,Θ) 
between the C/T-13910 variant and the marker DSS3014 were used. The first 1.2cM=1Mb 
inferred from the comparison of genetic and Physical maps of the interval D2S1334-
D2S2196, which contains the locus. The second 1cM=0.45 Mb, was estimated from the 
approximate physical distance between markers D2S3010-D2S2196 in the physical map 
(Fig.2, Study II) to the genetic distance between them from Marshfield genetic map.  
The last was the median of the first two estimations. 
(http://research.marshfieldclinic.org/genetics/Physical_Maps/chromosome2.htm). 
 
 
4.  RNA isolation, RT-PCR, and quantitation of RNA levels 
 
Duodenal biopsy specimens were homogenized using a sterile syringe and a 20 gauge needle. 
Total RNA was isolated by the guanidium thiocyanate method (RNeasy mini kit; Qiagen) 
followed by DNase treatment. RNA was reverse transcribed into complementary DNA 
(cDNA) using 20 pmol of LPH transcript specific reverse primers in exon one, exon 2, exon 
6, exon 10, exon 13, and exon 17, in a 20 ul reaction mixture containing 2 mmol/l Mg CI2, 50 
mmol/l Tris-HCI (pH 8.3), 75 mmol/l KCI, 10 nmol dNTPs, 20 mmol/l DTT, 24 U RNase 
inhibitor (RNAguard; Amersham Pharmacia Biotech), and 200 U reverse transcriptase, 
Superscript II (Invitrogen, Bloomington, Minnesota, USA). RT reactions were performed at 
+50ºC for 60 minutes and stored at - 20ºC. 
 
PCR was performed in 1 X PCR reaction in 50 ul containing 2 ul cDNA, with the previously 
described LPH transcript specific reverse primer and a corresponding forward primer, 30 
pmol biotinylated and 60 pmol non-biotinylated primer, and 1 U of Taq polymerase. 
PCR reactions were performed as described in genotype section. mRNA levels of each PCR 
product were quantified by the solid phase minisequencing method (Syvanen et al. 1993).  
The actual relative amounts of LPH mRNA derived from the two allele of LPH have been 
determined from the standard curve (Table 2 & Figure 2, study III). The standard curve was 
constructed from analysis of RNA samples mixed with known proportions of the two alleles 
of the informative coding SNP (cSNP GA 593). 
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5. Bioinformatics, population genetics software        
 
During the work for this thesis, flood of information was deposited in databases on daily 
basis and became an essential tool in molecular genetics. As an example, a considerable time 
has been spent in this project constructing a physical map for CLD locus, now can be done 
computationally in a few hours! 
 
Information can be searched with tools maintained by different servers, the most common 
being the National Center for Biotechnology Information (NCBI). Sequence alignments were 
carried out using BLAST programs (Altschul et al. 1997) and sequence variations were 
viewed in SNPs database. 
 
All statistical analyses carried in study V, except for the analysis of the LD intervals were 
calculated using the Arlequin software package version 2 (Schneider Stefan 2000). All 
haplotype estimations were made using the expectation-maximization procedure under 
default parameters (Excoffier and Slatkin 1995). Diversity indices were also calculated using 
default setting. The minimum-spanning tree among all haplotypes was calculated using 
Arlequin and was depicted manually for clarification by building a rooted tree in TreeView.  
 
All statistical analysis in study IV was performed using the BMDP statistical package 
(BMDP Statistical Software, Los Angeles, California, USA). All variables are expressed as 
mean ± standard error. Frequency differences were analysed with Pearson’s chi-squared test. 
Differences between groups were assessed by the non-parametric Kruskal-Wallis test. A p-
value less than 0.05 was considered to be statistically significant.   
 
The detailed web addresses of the programs and data bases mentioned here are provided in 
the electronic database information section page 82. 
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Results and Discussion 
 
1. Mapping of the CLD locus to chromosome 2q21  
 
The LPH gene had been previously assigned to 2q21 (Kruse et al. 1988; Harvey et al. 1993) 
and this guided us to analyze this region as a candidate region for CLD. We analyzed the 
segregation of 10 polymorphic markers flanking the LPH gene in 19 CLD families. 
Significant evidence of linkage (LOD score >3) were observed with eight markers spanning 8 
cM on chromosome 2q21 between marker D2S114 and D2S150. The highest lod score, 7.93, 
was obtained with marker D2S2385 (Table 1, study I).  
 
 
Among 38 CLD (affected) chromosomes, 19 different extended haplotypes could be 
constructed using 7 linked markers spanning 6 cM (Figure 3, study I). The expected founder 
haplotype: cent-6-4-4-2-2-3-5-tel, was present in 13 (34%) of disease chromosomes. The 
other haplotypes were separated from the founder haplotype by ancient recombination events. 
Based on the haplotype analysis the CLD locus could be restricted to 2 cM region between 
markers D2S314 and D2S2385, forming a core haplotype, 2-2, which was present on 82% 
(31/38) of affected chromosomes and on none of unaffected chromosomes. Furthermore, 
92% of affected chromosomes carried a single allele 2 of the marker, D2S2385, supporting 
the hypothesis of one major mutation underlying CLD among Finns. This finding is in 
according with the experience gained from analyzed Finnish disease heritage studies 
(Peltonen et al. 1999; Norio 2003a; Norio 2003b; Norio 2003c).  
 
A total of 7 markers analyzed, spanning an area >8 cM, provided evidence for LD (P<0.001) 
in disease alleles using HRRLAMB program, confirming the close linkage. At the time of the 
study the order of markers on 2q21 and location of LPH gene was not known precisely. The 
order of analyzed markers was defined by TNG RH mapping panel of the SHGC G3 map of 
chromosome 2 and by the RHMAP statistical package (Cox et al. 1990; Boehnke et al. 1991) 
(Figure 4, study I). A physical map using YAC clones and PAC clones over the CLD region 
was constructed and the position of the LPH gene was confirmed by RH mapping and by 
construction the physical map between marker D2S114 and D2S442. According to these 
studies the LPH gene was positioned outside the ancient core haplotype of CLD locus, 
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between D2S314 and D2S2385, and thus could be excluded as a causative gene for CLD. 
Supporting our conclusion, the mutation analysis of the cDNA coding for LPH gene and its 
promoter region in one of our CLD patients conducted previously by Italian group has so far 
not revealed any pathological sequence differences (Poggi and Sebastio 1991) and later on 
sequence analysis of 19 Finnish CLD patients shows that the C/T-13910 and G/A-22018 variants 
associated with adult-type hypolactasia do not correlate with the CLD phenotype providing 
supportive evidence of separate distinct locus underlying CLD on chromosome 2q21 (study 
II).  
 
When we retrospectively; compare the data obtained with the complete genomic sequence of 
the CLD region available now, the order of the markers remain the same but there is a 
difference in the distances estimates. For example, the distance between D2S314 and 
D2S2384 was ~200 kb instead of ~840 kb as determined by the RH map, obviously providing 
a non-sufficient level of resolution (Figure 4, study I). 
 
While tracing the ancestors of the CLD patients in the Finnish population a knowledge of the 
birth places of grandparent revealed an enrichment in the sparsely populated eastern and 
northern Finland which was inhabited during the late settlement after the 16th century (Norio 
2003b). The geographic distribution and wide LD interval (> 8cM) of CLD would indicate a 
young mutation, the history of which closely resembles that of infantile cerebellar ataxia, 
which has been estimated to have been introduced into the Finnish population 30-40 
generations ago (Varilo et al. 1996a; Varilo 1999). In addition, the genealogical data shows 
that the ancestors of the three parents (8%) carrying the more rare allele 7 of D2S2385 were 
born in three neighbouring villages close to the border between Russia and Finland, a finding 
suggesting that this allele represents another minor mutation underlying CLD. Currently the 
work to refine the CLD locus and to isolate the gene underlying CLD is underway. 
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2. Identification of lactase persistence variant 
 
2.1 Mapping & fine mapping of lactase persistence locus 
 
After mapping the locus for CLD on 2q21, a question we asked was where is the locus for 
adult-type hypolactasia? Previous studies have shown that the lactase persistence/non-
persistence trait is likely to be controlled by cis-acting element(s) residing within or adjacent 
to the LPH gene rather than by a variation in a trans-acting factor (Wang et al. 1995). In 
addition, further support for this hypothesis has been obtained by demonstration of a strong 
linkage disequilibrium (LD) across the 70 kb haplotype spanning the lactase gene (Harvey et 
al. 1995). 
 
To test for linkage, we analyzed seven polymorphic markers flanking the LPH gene in nine 
extended Finnish families with adult-type hypolactasia (Table 1, study II). Significant 
evidence of linkage with four markers (Lod score>3), with the highest lod score (7.67) at θ=0 
with marker D2S2196 were observed. The linked region was defined by recombination 
events between markers D2S114 and D2S2385, spanning total of 5 cM. LD was monitored 
conditional on the detected linkage, treating the allele frequencies and the recombination 
fraction as nuisance parameters (Goring and Terwilliger 2000b; Goring and Terwilliger 
2000c). Only marker D2S2196 showed significant evidence of LD (P=0.00010) in disease 
alleles, confirming the close linkage. 
 
 
These results led us to analyze more markers for the fine mapping of the region. One Contig 
spanning 223 kb was built over the region by assembling four BAC clones NH0034L23, 
NH0218L22, NH0318L13, and RP11-329I10, and the draft sequence of these BACs was 
searched for new markers. A total of 9 new polymorphic markers, three within the LPH gene 
(D2S3011, D2S3012 and D2S3013) were found and used for fine mapping (Figure 2, study 
II). Significant evidence of LD (P<10-4) was detected with 6 markers spanning 200 kb. The 
LD was strongest on the LPH gene, and 5´of LPH gene, whereas the markers 3´of LPH gene 
showed no evidence of LD (Table 1, study II).  
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Extended haplotypes were constructed using the markers (D2S3011-D2S3012-D2S3013-
D2S3015-D2S3014-D2S3016-D2S3017) in 9 clinically phenotyped Finnish families. A total 
of 54 non-persistence alleles and 33 persistence alleles were identified. One major haplotype 
was present in 20 persistence alleles (60%) versus 3 of the non-persistence alleles (5%), 
whereas a more diversity of haplotypes was observed in non-persistence alleles. The 
remaining 13 persistence alleles (40%) differed from the ancestral haplotype in a manner; 
which was consistent with interruptions of the haplotype by ancient recombinations. Based 
on the conserved haplotype, the locus for lactase persistence could be restricted to a 47 kb 
interval between markers D2S3013 and D2S3014 (Figure3, study II). Furthermore, the 
highest LD was observed with markers D2S3012 and D2S3014 that showed the conserved 
core haplotype 5-2 of lactase persistent. Consistent with our data, one major lactase 
persistence haplotype using SNPs has been reported in other populations by others (Harvey et 
al. 1995; Harvey et al. 1998). However the earlier efforts to monitor that haplotype were 
focused solely on LPH gene and sequence in its immediate vicinity (Harvey et al. 1995). 
 
 
2.2 Identification of the DNA variants associated with lactase 
persistence in Finnish families 
 
We analyzed the 47-kb region in DNA of seven family members, four with lactase 
persistence and three with non persistence. The selection of the individuals for mutation 
screening was based on haplotype analysis. We chose to include individuals with 
homozygous lactase non persistence that had identical haplotypes to individuals with 
definitive heterozygous lactase persistence to ensure that we selected the right culprit (Figure 
6). The importance of that can be seen clearly in the case of SNPs:  G/A-8540 and C/G-8630 , in 
which complete co-segregation with lactase persistence phenotype is seen except with the key 
sample DIV4 (CIV3, and DIV4, table 2, figure 2; study II).  
 
The region contains only one known gene, minichromosome maintenance deficient 6 
(MCM6), that covers 36 kb of the critical 47 kb (Harvey et al. 1996). No sequence changes in 
the coding region of MCM6 were detected.  For MCM6, unlike LPH, measurements of the 
mRNA expression in adult small intestine do not show person-to-person variation and the 
expression does not show restricted tissue distribution. There is no correlation in the levels of 
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the steady state transcripts of MCM6 and LPH (Harvey et al. 1996). These result suggest that 
there are no functionally significant tissue specific or developmental cis-acting elements shared 
by the two genes (Harvey et al. 1996) . We identified a total of 52 non-coding variants in the 
critical MCM6 region: 43 SNPs and 9 deletion/insertion polymorphism (Table 2, study II). 
Only two of the variants (C/T-13910, G/A-22018) showed complete co-segregation with the 
lactase persistence trait in families (Tables 2, 3; study II). All family members with non 
persistence were homozygous with respect to both C-13910 and G-22018. The C/T-13910 variant is 
located in intron 13 of MCM6 gene 13910 bp toward 5´of the initiation codon of LPH and the 
G/A-22018 variant in intron 9 of MCM6 gene 22018 bp upstream of the first ATG codon of 
LPH.  
Family B
IV4 IV9IV3 IV17
Family A
IV8
Family B
IV16 IV3 IV4
Family C
IV3 IV4
Family D Family E
III2
D2S114 9 1 8 1 9 1 9 9 2 3 3 9 6 1 9 9 9 6 4 5 3 1 
P6112 9  11 9 10 9 10 9 11 12 10 10 12 7 8 5 11 9 1 9 9 9 6 
D2S1334 9  11 9 10 9 10 9 11 12 10 10 12 7 8 5 11 9 1 9 9 9 6 
D2S3010 9  11 9 10 9 10 9 11 12 10 10 12 7 8 5 11 9 1 9 9 9 6 
D2S3011 1 6 6 6 1 6 1 6 6 6 6 6 6 6 6 5 6 6 6 6 5 5 
D2S3012 3 3 4 4 3 4 3 3 4 4 4 5 4 4 5 2 4 4 2 4 2 2 
D2S3013 1 4 3 2 1 2 1 4 2 4 4 5 3 2 5 7 2 3 7 3 7 7 
D2S3015 4 5 5 5 4 5 4 5 5 5 5 5 5 5 5 3 5 5 3 5 2 1 
D2S3014 5 5 2 4 5 4 5 5 2 2 2 5 2 2 5 5 2 2 4 2 5 5 
D2S3016 4 5 5 5 4 5 4 5 5 5 5 3 5 5 3 3 5 5 3 5 3 1 
D2S3017 5 3 6 6 5 6 5 3 6 6 5 6 6 6 2 1 6 5 3 6 1 5 
D2S3018 8 9 3 3 9 3 9 8 4 3 3 2 3 2 4 4 3 5 4 5 5 7 
D2S2196 5 9 6 1 5 1 5 9 3 6 6 9 6 5 5 9 5 4 4 6 6 5 
D2S442 1 4 5 5 1 5 1 4 4 5 5 5 3 4 4 1 5 5 3 4 5 5 
D2S314 4 5 6 5 4 5 4 5 4 5 5 9 5 4 4 5 5 9 5 2 5 8 
D2S2385 5 5 10 5 5 5 5 5 6 6 1 5 6 5 5 4 5 8 1 5 10 10 
 
Figure 6. The haplotypes of the seven family members used for sequencing the 47 kb region.
 
 
 
The restriction of the critical region to 47 kb has been criticized since the localization was 
claimed to rely on data from two chromosomes that differ from ancestral chromosomes at 
only a single marker (Grand et al. 2003; Swallow 2003; Bersaglieri et al. 2004). So, these two 
chromosomes could be derived from a recent mutation at one marker rather than from a 
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recombination event. However, several lines of evidence would support our conclusion. First, 
the numbers reported in our paper for marker D2S3014 (2/33; 6%) are biased because these 
families was ascertained through lactase non-persistence probands (Enattah et al. 2002). The 
analysis of allele 4 of marker D2S3014 in 144 unrelated individuals with verified lactase 
persistence reveals the prevalence of 12%, identical with the prevalence in 118 unrelated 
individuals with verified lactase non persistence (unpublished data). The high frequency of 
allele 4 in Finnish population would support an ancient recombination event. Second, based 
on the LD, the highest p values for LD occurred at the markers D2S3012 (located within the 
intron two of the LPH gene) and marker D2S3014, the finding guiding to the 5´end of the 
LPH gene.  
 
 
2.3 Sequencing of the regions flanking the lactase persistence/ 
nonpersistence locus 
 
We extended the sequencing efforts to comprise the whole genomic region of LPH gene and 
we also extend the sequence effort to the marker D2S3016 (Figure 2, study II). The rational 
for this effort was to find any other sequence variations, within the LD regions, co-
segregating with adult-type hypolactasia. A total of 76 SNPs, and 8 deletion insertions among 
the 7 individuals were identified in the 70 Kb regions covering the entire LPH gene and the 
5`of marker D2S3014. None of the variation detected completely co-segregated with adult-
type hypolactasia.  
 
Within LPH region, a total of 71 variant were observed; 64 SNPs and 7 del/Ins 
polymorphisms, in addition to 3 microsatellite markers. We detected variations in all introns 
of the LPH gene except introns 8, 10, 15, and 16.  
 
A 3640 bp deletion/insertion within intron one of LPH was monitored in the whole family 
material, and in sample set from different populations. Although the lactase persistence T-
13910 allele was present almost exclusively in back-ground of the deletion allele, the deletion 
allele was present in all population tested: in Africa, Asia, and Europe, indicating that the 
deletion allele was ancient and probably occurred before modern human comes out of Africa.  
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On average 1 SNP/ 750 bp was thus identified within LPH gene, the coding regions of the 
LPH gene reveals 8 cSNPs .These variations located in exons 1, 2, 6, 10, 13, 16 and 17. 1 
SNP/904 bp was identified within the 47 kb adult-type hypolactasia locus and within the 
region between markers D2S3014-D2S3016 there was 1 SNP/ 1154 bp (Tables 3 & 4).  
Overall in the 115 kb region sequenced, there is on average 1 SNP/ 845 bp, with only one 
Variant, C/T-13910, co-segregating completely with the lactase persistence/ non persistence 
phenotype. 
 
Table 3. The variations identified within LPH gene. 
Positiona Variant Lactase 
persistence 
Lactase 
persistence 
Lactase 
non-persistence 
  (Homozygous ) (Heterozygous)    
  BIV4 AIV3 BIV8 CIV3 BIV9 DIV4 EIII2b
+582 / E1c T→ C TT TT TC TT CC ND CC 
+982 C→ A CC CC CA ND AA CA ND 
+1046 A→ G AA AA AG ND GG AA ND 
+2876 T→ C TT TT TC TT CC TT CC 
+3706 ∆/I3640 bp ∆ ∆ ∆ ∆ ∆I ∆ ∆ II ∆I II 
+7936/E2 G→ A GG GG GG GG GG N AA 
+9070 C→ G CC CC CG CC GG GC GG 
+9303 C→ T CC CC CC CC CC ND TT 
+9404 T→ C TT TT TT TT TT ND CC 
+9715 ∆/I TCTC II II II II II ND ∆ ∆ 
+10204 T→ A TT TT TA TT AA TA AA 
+10651 G→ T GG GG GG GG GG GG TT 
+11727 T→ G TT TT TG TT GG GT GG 
+11845 G→ T GG GG GG GG GG GG TT 
+11857 A→ G AA AA AG AA GG AA AA 
+11860 G→ A GG GG GG GG GG GA AA 
+12502 G→ A GG GG GG GG GG GA AA 
+12658 C→ T CC CC CC CC CC CT TT 
+13362 G→ A GG GG GG GG GG GA AA 
+14147 T→ A TT TT TT TT TT TA AA 
+15493 T→ C TT TT TT TT TT TC CC 
+15876 T→ C TT TT TT TT TT TC CC 
+15991 A→ G AA AA AA AA AA AG GG 
+16837 T→ C TT TT TC TT CC TC CC 
+17509 C→ G CC CC CC CC CC CC GG 
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+18288 C→ T CC CC CT CC TT ND CC 
+18399 G→ A GG GG GA GG AA ND AA 
+18426 A→ T AA AA AT AA TT ND TT 
+20150 G→ A GG GG GA GG AA GA AA 
+20492 T→ G TT TT TG TT GG ND TT 
+20646 T→ C TT TT TC TT CC ND TT 
+22108 G→ A GG GG GA GG AA GA AA 
+22519 G→ A GG GG GA GG AA GG GG 
+23487/E6 A→ C AA AA AC AA CC ND AA 
+24065 A8→A7 A8 A8 A8 A8 A8 A7 A8 A8 A7 A7 A8 A8 A8 A8 
+24369 T→ C TT TT TC TT CC TT TT 
+25253 ∆/I T II II II II II II ∆ ∆ 
+25418 A→ G AA AA AG AA GG AA AA 
+26391 G→ C GG GG GC GG CC GC CC 
+26694 A→ T AA AA AT AA TT AA AA 
+26845 A→ G AA AA AG AA GG AA AA 
+28063 T→ A TT TT TA TT AA TT TT 
+30232 C→ T CC CC CC CC CC CC CT 
+30463  ∆/I T II II II II II II ∆ ∆ 
+30484 A→ C AA AA AC AA CC ND CC 
+33358 C→ T CC CC CT CC TT CC CC 
+35438 G→ C GG GG GC GG CC GG GG 
+36080/E10 G→ C CC GG CG GG GG GG GG 
+36214/E10 C→ T CC CC CT N TT ND CC 
+38684 A→ G AA AA AG AA GG AG AA 
+40530 A→ G AA AA AG N GG ND AA 
+41369 A→ G AA AA AG AA GG AG GG 
+41883 G→ A GG GG GA GG AA GG GG 
+42506 G→ A GG GG GG GG GG AG AA 
+43029/E13 G→ A GG GG GA GG AA ND GG 
+43798 T→ C TT TT TT TT TT TC CC 
+43888 G→ C GG GG GG GG GG GC CC 
+43901 G→ A GG GG GG GG GG GA AA 
+44166 A21→A20 A21/21 A20/20 A21/21 ND A21/21 A20/20 A20/20 
+45059 C→T TT ND ND TT ND ND CC 
+45170 A→G AA ND ND AA ND ND GG 
+45506 I/∆TAT ∆∆ ∆∆ ∆∆ ∆∆ ∆∆ ∆∆ II 
+45507 A→T AA AA AT AA TT AT TT 
+45513 A→T AA AA AT AA TT AT TT 
+45679 G→C GG GG GG GG GG GC CC 
+46177 G→T GG GG GG GG GG GT TT 
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+46186 C→T CC CC CC CC CC CT TT 
+46448 C→T CC CC CC CC CC CT TT 
+46948 A→G AA AA AG AA GG AG GG 
+48533 A→G AA AA AG AA GG AG GG 
+51334/E16 C→T CC TT CT ND TT ND TT 
+52577/E17 C→T CC CC CT CC TT ND TT 
a The number is from initiation translation codon (ATG) of the LPH gene (contig NT 
005058), b the individuals sequenced from the Finnish families studied, c exonic SNP, ND: 
not determined 
 
 
 
Table 4. The variations identified in the region between markers D2S3014 and D2S3016 
Positiona Variant Lactase 
persistence 
Lactase 
persistence 
Lactase 
non-persistence 
  (Homozygous ) (Heterozygous)    
  BIV4 AIV3 BIV8 CIV3 BIV9 DIV4 EIII2b
- 45499 A→G AA N AG AA GG ND ND 
- 46662 A→G AA AA AG AA GG AA AA 
- 47713 T→C TT TT TC TT CC C TT 
- 49181 A→G AA ND AG AA GG ND GG 
-52181 G→A GG GG GA GG AA ND GG 
- 54244 A11→A10 A11/11 A11/11 A11/10 A11/11 A10/10 A10/10 A11/11 
- 57374 G→A GG GG GG GG GG GA AA 
- 57775 G→A AA AA AA AA AA AG GG 
- 57808 G→A AA AA AA AA AA AG GG 
- 58140 G→A GG GG GA GG AA GG GG 
- 58236 T→C TT TT TC TT CC TC TT 
- 59133 C→T CC CC CC CC CC ND TT 
- 59210 A→T AA AA AA AA AA ND TT 
a The number is from initiation translation codon (ATG) of the LPH gene (contig NT 
005058), b the individuals sequenced from the Finnish families,  ND: not determined 
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2.4 Genotype-Phenotype correlation & implication 
 
We analyzed the two variants in Finnish DNA samples isolated from a total of 196 intestinal 
biopsy specimens with biochemically determined disacchridase LPH activity. All 59 samples 
showing primary lactase deficiency were homozygous for to the C-13910 allele of the C/T-13910, 
6 were heterozygous for to the G/A-22018 variant and the remaining 53 were homozygous with 
respect to the G-22018 allele. Among the 137 cases showing lactase persistence, none were 
homozygous with respect to alleles C-13910 and G-22018, at C/T-13910 and G/A-22018 respectively: 
74 were homozygous for alleles T-13910 and A-22018, with 63 being heterozygous at both 
positions. All 53 non Finnish cases with verified disacchridase deficiency (23 from S.Korea, 
22 from Italy and 8 from Germany) were homozygous CC-13910 with respect to C/T-13910. One 
Italian sample was heterozygous GA for G/A-22018, whereas the remaining 39 cases were 
homozygous GG-22018 at this position (Table 3; study II). All 7 lactase persistence subjects 
from Italy were heterozygous CT and GA for C/T-13910 and G/A-22018 respectively.  
 
Thus far, all the adult biopsy specimen results studied in study II (196 Finns, 23 South 
Koreans, 30 Italians, and 8 Germans) and in addition to 52 Finns studied in study III, show 
perfect correlation between the genotype of the C/T-13910 variant and phenotype of lactase 
persistence. 
 
To correlate the C/T-13910 genotypes with disaccharidase activity in 222 Finnish adults 
patients includes in the studies mentioned above aged from 18 to 83 years (unpublished data), 
the biopsies were assayed for lactase, sucrase and maltase activity. The analysis of 
disacchridase activities in these samples shows a strong correlation between lactase activity 
and trimodal distribution of the C/T-13910 genotypes (P<0.0001).  The mean level of lactase 
activity among CC-13910 genotype was 6.86±0.35 U/g protein, among CT-13910 genotype were 
37.8±1.4 U/g protein, and among TT-13910 genotype were 57.6±2.4 U/g protein. In addition, 
our data also show significant differences in maltase activities among different C/T-13910 
genotypes (P=.005). For sucrase activity, there was no significant differences among the C/T-
13910 genotypes (P=0.14). However, there were no statistical differences in lactase (P=0.84), 
sucrase (P=0.18), and maltase activities (P=0.24) among different age groups. These results 
shows that the C/T-13910 genotypes correlate with a trimodal distribution of lactase activity, in 
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addition our data show that age per se has no significant effect on the disaccharidase activity 
in adults aged between 18-83 years (Tables 5 & 6). 
 
Table 5.  Distribution of disaccharidase activities in relation to the C/T-13910 genotypes. 
Disaccharidasea                                        Genotype    
  C/C-13910 C/T-13910 T/T-13910 Total Pb 
                N  56 83 83 222  
Lactase  6.86±0.35(3-16) 37.8±1.4(21-99) 57.6±2.4(20-127) 37.4±1.7(3-127) <0.0001 
Sucrase  77.2±3.7(40-172) 87.2±3.8(35-240) 83.2±4.3(24-260) 83.2±2.4(24-260) 0.14 
Maltase  287.7±13.2(159-599) 342.0±13.5(161-868) 305.5±14.5(140-887) 314.6±8.2(140-887) 0.005 
L/S ratioc  0.09±0.005(0.03-0.2) 0.46±0.02(0.2-1.6) 0.73±0.02(0.25-1.35) 0.47±0.02(0.03-1.6) <0.0001 
a disaccharidase activities are expressed as U/g protein, mean±SE (range). 
 b The p value based on Kruskal-Wallis test. clactase/sucrase ratio 
 
 
 
Furthermore, 329 intestinal biopsy specimens from children and adolescents aged from 0.1 to 
20.2 years were assayed for lactase, sucrase and maltase in other study by our team to 
determine the age of down-regulation of the lactase activity in children of African, Finnish 
and other Caucasian origins. The results shows that the C/C-13910 genotype was associated 
with very low lactase activity (<10 U/g protein) in all children >12 years of age with a 
specificity of 100% and sensitivity of 93% of the genetic test (Rasinpera et al. 2004). These 
data and the unreliability of the indirect diagnostic methods of lactase non-persistence, such 
as the lactose tolerance test (Arola 1994), and the tedious measurements of lactase activity in 
jejunal biopsy sample specimens highlights the usefulness of a reliable DNA test as a first-
stage screening test for adult-type hypolactasia. The functional evidence of the variant C/T-
13910 has also been  recently reported by others (Olds and Sibley 2003; Troelsen et al. 2003b) 
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Table 6.  Distribution of disaccharidase activities in different lactase variant genotypes for  
various age groups. 
  Age groups (years)   
Disaccharidasea 18-39 40-59 60-83 Total Pb
 N 84 94 44 222  
Lactase  35.6±2.4 39.3±3 37±3.5 37.4±1.7 0.84 
Sucrase  77.3±2.8 86.6±4.5 87.4±4.5 83.2±2.4 0.18 
Maltase  298±11 326±16 324±13 315±8 0.24 
L/S ratioc  0.48±0.03 0.48±0.03 0.43±0.04 0.47±0.02 0.70 
a disaccharidase activities are expressed as U/g protein, mean±SE (range). 
 b The p value based on Kruskal-Wallis test. clactase/sucrase ratio 
 
 
 
2.5 LD analysis of the LPH locus 
 
We analyzed a total of 24 SNPs and one deletion/insertion polymorphism in 122 Finnish trios 
to analyze the intermarker LD and the haploblock boundaries at the lactase persistence locus. 
The analyzed region spans over 0.8 Mb, reaching from 470 kb 5` of the LPH first ATG 
codon, to 400 kb 3 ´ from the LPH ATG codon  (Figure 1; study V). This set of markers 
should be sufficient to define the major haploblocks of the critical LPH region in various 
populations. 
 
Inter-marker LD was determined for the alleles carrying lactase persistence variant, T-13190, 
and for the alleles carrying the lactase nonpersistence variant, C-13910, using Genepop program 
(Figure 3, study V). The pattern of LD on lactase persistence alleles show some level of LD 
(P<0.05) between all the marker pairs tested as can be observed in the plot indicating the 
pair-wise LD (Figure 3a-c, study V). However, lactase nonpersistence alleles showed less 
LD between most of the markers, resulting in a more rapid decay in LD intervals. These 
results are in good agreement with the previous data obtained with microsatellite markers that 
showed a significant LD up to 350 kb flanking the LPH gene (Enattah et al. 2002).  
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In order to further explore the genomic structure of the LPH region, we analyzed the 
haploblocks over the region. One haploblock extends over the complete genomic region 
covering over 700 kb in the lactase persistence alleles, whereas in the lactase nonpersistence 
alleles three blocks can be defined with sizes of 300 kb, 250 kb and >300 kb (Figure 3 a-f, 
study V). This can also be seen when a varying number of markers is left outside the 
predicted haplotype blocks: the haploblock structure shows a more rapid decay in lactase 
nonpersistence alleles than in lactase persistence alleles (Figure 3g-i, study V). These results 
in good agreement with a recent study which shows that the haplotype containing lactase 
persistence alleles T-13910 and A-22018 is almost identical over 800 kb in European Americans 
(Bersaglieri et al. 2004).  
 
 
2.6 Analysis of the DNA-Variants in different populations 
 
The prevalence of lactase nonpersistence varies greatly in different populations, from <5% in 
Northern Europe to almost 100 in South East Asia (Sahi 1994a). In order to explore the 
prevalence of the C/T-13910 in different populations, we screened 938 DNA samples from 
anonymous Finnish blood donors collected from small parishes in Eastern and Western 
Finland, and in addition 92 Utah, 17 French, and 96 African-Americans samples. In Finns, 
the overall prevalence of lactase non-persistence genotype CC-13910 (170 cases) was 18.1%., 
with lower prevalence in the sample from western region (16.8%) than in the eastern region 
(18.9%, P=0.02, 1 df) Table 7. The prevalence of genotype CC-13910 in French was 41.2%, in 
Utah was 7.6%, and in African-American was 79.2 %. These figures were in good 
agreements with epidemiological data (Cuddenec et al. 1982; McLellan et al. 1984).  
 
The test for heterogeneity of the allele frequencies was performed with maximum likelihood 
methods under the assumption of Hardy-Weinberg Equilibrium (HWE). No deviations from 
HWE were detected among allele frequencies. All pairwise comparisons: between all Finland 
and Utah, all Finland and France, Utah and France, are extremely significant (p <10-3) except 
for eastern vs western Finland which is marginal (p=0.02) (Table 7). 
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Table 7. Prevalence of the C/T-13910 variant in population samples. 
DNA samples (n) 
 
Genotype Allele frequency %  (CC) 
genotype 
Reported 
Prevalencea  
 CC CT TT C T   
                                               
 
                                                  P valueb 
I. Finnish population:         
1. Eastern regions (571) 108 287 176 0.440 0.560 18.9%  Eastern Vs Western Finland:   0.018  
2. Western regions (367) 62 159 146 0.385 0.615 16.8%  
                Total        (938) 170 446 322 0.418 0.582 18.1% 17% 
All population  
indentical Vs  different :   0.0000001        
II. CEPH parents:        Utah Vs France :                0.000003    
1. Utah families     (92) 7 33 52 0.255 0.745 7.6% 5% All Finland Vs Utah :         0.0000005  
           2. French families  (17) 7 9 1 0.676 0.324 41.2% 37% All Finland Vs France:        0.0001        
III. African Americans (AA) (96) 76 15 5 0.87 0.13 79.2% 78 % All Finland Vs AA:             < 10-10            
A total of 938 DNA samples of anonymous Finnish blood donors from small parishes in Eastern and Western Finland, 109 DNA samples from 
CEPH parents, and 96 samples from African Americans. P values for heterogeneity among allele frequencies were estimated by maximum 
likelihood methods, under the assumption of HWE assuming.  a references for the reported population prevalence of adult type hypolactasia 
(Simoons 1978,Sahi  1994a) 
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The two variants C/T-13910 and G/A-22018 were in almost complete LD. The LD between them 
was calculated in the random Finnish DNA samples cohorts and reveals D´= 0.984 (χ2 (1 df) 
=42.41, P-value=7.62x10-11) Table   8.   
 
 
Table 8. LD between C/T-13910 and G/A-22018 variants in random Finnish DNA-samples.  
 Genotype at C/T-13910 Total D` χ2(1 df) P-value 
 CC CT TT     
Genotype at G/A-220018         
GG 162 2 1 165    
GA 6 440 3 449    
AA 2 4 318 324    
Total 170 446 322 938 0.984 42.41 7.62x10-11 
LD was calculated using D`statistic, the p value is the significance of D`from 0 as described 
in the Methods. 
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2.7 Species comparisons & Similarity Searches  
 
The down regulation of lactase enzyme after weaning is a characteristic feature in mammals. 
Subsequently, sequence comparisons in different species could shed light on the functional 
relevance of sequence elements. We sequenced the relevant parts of intron 9 and part of 
intron 13 of the MCM6 gene of a Baboon (Papio hamadryas). Genotype GG and CC was 
present in Baboons DNA at SNPs G/A-22018 and C/T-13910. This would imply that alleles 
G and C, respectively, reflect the appearance of the ancient allele in which the mutations have 
occurred to produce the persistent status. Comparing the human sequence with other primate 
sequences (Orange-utans, Chimpanzee, Gorilla Gorilla, Rhesus Monkeys, and Baboons) also 
reveals the presence of lactase non-persistence alleles C-13910 and G-22018 at the Variants C/T-
13910 and G/A-22018 respectively in all of them. This provides evidence that the ancestral state 
of the human lactase gene is the non persistence form. In contrast, searching mouse sequence 
revealed no conserved sequence between humans and mice in the regions flanking the critical 
variants C/T-13910 and G/A-22018. 
 
Sequence similarity of the region flanking the variants C/T-13910 and G/A-22018 shows that C/T-
13910 variant is located within a short region (100 bp) that has a similarity to LINE 2 (L2) 
repeat element, whereas the G/A-22018 is located within full length Alu repeat element.  
LINEs are long interspersed nuclear elements, considered to be one of the most ancient 
transposable elements in eukaryotic genomes. The full-length consensus sequence is 6.1 kb 
comprising of two open reading frames and an internal promoter within a region of 5`-UTR 
preceding ORF1 (Hwu et al. 1986; Smit 1996). In the human genome, three distantly related 
LINE families are found: LINE1, LINE2 and LINE3. Analysis of the draft genome sequence 
shows that LINEs comprise 20.42% of the human genome sequence, LINE2 family 
comprises 3.22% of the human genome sequence (Lander et al. 2001). The functional role of 
LINEs has been reported for L2 which has been shown to modulate the gene expression of 
annexin VI, potent T-cell-specific silencer (Donnelly et al. 1999). Concerning the location of 
the G/A-22018 variant the human genome contains 500,000 copies of an Alu sequence, which 
is a 281-bp short interspersed nucleotide repeat (Britten 1994). They have been frequently 
identified in the transcriptional regulatory regions of  numerous genes (Maouche et al. 1994). 
 
A search of the TRNASFAC database (http:/motif.genome.ad.jp/) for cis regulatory elements 
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revealed high score similarity for affects stress-response element (STRE) and alcohol 
dehydrogenase gene regulator 1 (ADR1) binding sites at C/T-13910, and for Sp1 binding site at 
G/A-22018. ADR1 is a transcriptional activator that regulates genes involved in carbon source 
utilization in Yeast (Sloan et al. 1999). ADR1 expression is repressed 3-20- fold when 
glucose is present in the medium (Blumberg et al. 1988; Dombek and Young 1997). The 
stress response element (STRE) known by the consensus core sequence AGGGG is able to 
mediate transcription induced by various forms of stress including carbon source starvation, 
heat shock and severe osmotic and oxidative stresses (Martinez-Pastor et al. 1996). Sp1 is a 
transcription factor whose interactions with other proteins leads to diverse effects on gene 
transcription, having a stimulatory effect in most cases, but also a negative effect on 
transcription (Shou et al. 1998). The potential functional importance of STRE, ADR1 and 
SP1 binding sites to the lactase persistence allele remains to be determined.  
 
 
2.8 Mechanism of retaining lactase expression (lactase persistence) 
 
We studied the effect of C/T-13910 and G/A-22018 on the steady state transcript level of the of 
LPH gene in intestinal mucosa by relative quantitation of the allele-specific transcripts by 
RT-PCR followed by minisequencing. The results showed that the expression level of LPH 
mRNA in individuals with T-13910 and A-22018 alleles is several times higher that found in 
individuals carrying C-13910 and G-22018 alleles (Figures 3 and 4; study III). This finding 
suggests that these two SNPs are associated with the transcriptional regulation of the LPH 
gene. However, the molecular mechanism underlying the persistence of high intestinal lactase 
activity; still needs to be verified.  
 
Recently reported studies have indicated that the DNA region of C/T-13910 contains a strong 
enhancer, and it has been suggested that both lactase persistent T-13910 allele and lactase non 
persistent C-13910 allele have enhancer activity (Olds and Sibley 2003; Troelsen et al. 2003b). 
However, the T-13910 allele enhances the LPH promoter activity several times more than the 
C-13910 allele when analyzed in differentiated Caco-2 cells. In addition, a nuclear factor from 
an intestinal and non-intestinal extract on EMSA (gel shift assay) binds strongly to the T-13910 
allele whereas the binding to the C-13910 allele is much weaker. Furthermore, compared with 
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the C/T-13910 region, the G/A-13910 variant region result in minimal enhancements of the lactase 
promoter (Olds and Sibley 2003; Troelsen et al. 2003b).  
Although these pieces of evidence imply the direct transcriptional regulation role for these 
variants, studies looking at the effect of the variants in a stably transfected cell lines or in 
animal models will be necessary to confirm a role for the C/T-13910 variant region in 
specifying lactase persistence or non persistence. 
 
 
2.9 Adult-type hypolactasia: A more complex genetic condition?  
 
Historically, it was well known from the beginning that lactase persistence that represents the 
abnormal condition. Unfortunately earlier family studies referred to the adult-type 
hypolactasia, implying an abnormal state. This concept has it's root in the fact that these two 
conditions are considered as two faces of the same coin: if you are not hypolactasic then you 
are lactase persistent and vis versa. This is true from genetic analysis view point (family 
studies, linkage analysis), as you will end up with the same result if you use adult-type 
hypolactasia a recessive condition or lactase persistence as dominant condition. Multiple lines 
of evidence indicate that we have here identified the allelic variant(s) resulting in the lactase 
persistence phenotype. However, the situation in vivo is more complex. The expression of the 
LPH gene has been reported to be regulated by multiple transcription factors and their 
interactions (such as the caudal homologue Cdx2, HNF1α, HOX11, FREACs and GATA 4,5 
and 6 factors (Troelsen et al. 1992; Troelsen et al. 1994b; Troelsen et al. 1997; Fitzgerald et 
al. 1998; Hollox et al. 1999; Spodsberg et al. 1999; Fang et al. 2000; Mitchelmore et al. 2000; 
Fang et al. 2001; Krasinski et al. 2001; van Wering et al. 2002a; van Wering et al. 2002b; 
Troelsen et al. 2003a) and to influence the decline of the LPH enzyme after childhood. 
 
Lactase non persistence (adult-type hypolactasia) should perhaps not be considered a 
traditional recessively inherited condition, but instead it could be considered as a polygenic 
condition because it is a normal physiological developmental condition, involves interaction 
of multiple gene products (transcription factors) with 1-2 kb of the promoter of LPH to 
control the decline of lactase. We would like to propose that adult-type hypolactasia and 
lactase persistence could at the molecular level represent two different conditions affecting 
intestinal cells.  
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3. Association of lactase persistence with human diseases; type 1 
and 2 diabetes as an example 
 
In humans, intestinal lactase activity is increased in diabetes and has been shown to 
normalize during insulin treatment (Tandon et al. 1975). In a recent study a high frequency of 
lactose absorbers (lactase persistence, LP) was observed among diabetic patients in Sardinia 
(Meloni et al. 2001). Milk and milk products form an essential part of the Western diet. In 
Finland the annual consumption of milk products with an average of 220 kg milk products 
per capita, and thus a high frequency of lactose absorption among diabetic patients is 
intriguing. 
 
To test this relationship further, we genotyped 2542 Finnish subjects for the C/T-13910 
polymorphism including 1455 type 1 diabetes (Pettersson-Fernholm et al. 2003), 615 type 2 
patients, and 446 control subjects (Groop et al. 1996) (Table 1, study IV).  The frequency of 
LP genotypes (CT and TT) was 84.7% in type 1 diabetic patients and thus did not differ from 
the frequency of 81.9% in the general population (Study II). Patients with the CC-genotype 
were slightly younger and had a shorter duration of diabetes (P=0.02) (Table 2, study IV). 
The frequency of CT and TT genotypes among 465 type 2 diabetic patients from Western 
Finland was 91.7 % vs. 91.3% in 446 control subjects from the same region (P=NS). Among 
120 patients with type 2 diabetes patients from Eastern Finland, the prevalence of the 
persistence CT and TT- genotypes was 82.5 % vs. 81.1% in the general population of Eastern 
Finland (study II) (Table 2, study IV). The LP genotypes were associated with waist to hip 
ratio (WHR) in type 2 diabetic females from Western Finland (P=0.03) and in type 2 diabetic 
males from Eastern Finland (P=0.03) (Table 2, study IV). Thus the analysis of 2516 
subjects, could not demonstrate any association between LP genotypes and type 1 or type 2 
diabetes. This suggests that lactase persistence is not a risk factor for diabetes in Finland, and 
the finding contradicts the results obtained in the Sardinians (Meloni et al. 2001). It also 
highlights the methodology and importance of subject selection in a case-control study of 
lactase persistence to avoid false positive associations when the prevalence of the condition 
varies considerably among and between populations (Sahi 1994). 
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4. Tracing the history of lactase persistence 
 
4.1 Prevalence & geographic distribution of lactase persistence variant 
      in global populations             
 
The population frequencies of lactase persistence allele were examined in 37 population 
samples from different geographic areas (Figure 3, study V).  Again we use lactase 
persistence in the prevalence figures instead of hypolactasia. The data are summarized in 
Table 1, study V. The frequency of the lactase persistence (C/T-13910) variant in various 
populations systematically reflected the reported prevalences of lactase persistence, 
determined by disaccharidase activities in intestinal biopsies, and/or lactose tolerance tests in 
these populations (Sahi et al. 1973; Simoons 1978; Sahi 1994a; Hollox et al. 2001).  
 
As expected, the lactase persistent allele was almost non existent among East Asians. In the 
Finno-Ugric populations, the prevalence of lactase persistence (measured by C/T-13910  and 
T/T-13910 genotypes)  gradually increases from <10% in the areas east of Ural (Ob-Ugric 
speakers) to 30-60% in the populations west of Ural (Komi, Udmorts, Mokshas, Erzas, 
Saami) reaching the peak prevalence of 84% in Finland. In West Asia we analyzed 12 
different ethnic groups from Pakistan and found the prevalence distribution to show a gradual 
increase of lactase persistence allele from north-east (4 out of 6 groups shows < 10% 
frequency) to south-west (the frequency range in other 6 groups from 28% to 65%). The 
exceptional prevalence in Kashmiri and Pathan regions could reflect a very young history of 
these two ethnic groups, in north from Pakistan. Among Iranians, nomadic Iranians and 
Arabic samples from Iraq, Syria, Lebanon, the region where the agriculture and 
domestication of animals is considered to begin, a relatively low frequency of lactase 
persistent allele (< 20%) was observed  (Table1, study V). Among Europeans populations, 
the prevalence in southern part of Italy is as low as 11%, in line with epidemiological data. In 
France, the frequency is as high as 59%. In Basques, an isolated population from the 
Paleolithic era of Europe, the prevalence of lactase persistence is very high, up to 92% like 
the Utah population in Northern America, population with northern European ancestry. In 
Africa, the prevalence in East (Somalia) is low (<10%), whereas in Northern Africa moderate 
prevalence of lactase persistence allele is observed in Moroccans 49%, and nomadic 
population (Saharawi)  63%. In Subsharan Africa, a high frequency of lactase persistence was 
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found among the Sudanese-Fulanese tribe living 11 km east of capital city of Sudan 
(Khartoum) 70%. This result was in contrast to previous report in Sudanese samples which 
show the lack of lactase persistence allele. The panel of mixed African-American DNA 
samples showed a prevalence of 12% (Table 1, study V). 
 
 
4.2 Identification of the likely place of origin based on the haplotype analysis 
 
To gain a better understanding of the allelic diversity underlying lactase persistence/non-
persistence, we selected a subset of SNPs to analyze the detailed haplotypes in 37 
populations. A total of 8 SNPs and one deletion/insertion polymorphism were monitored, 
located in 30 kb area flanking the lactase variants (Figure 5). The observed haplotypes were 
ranked based on their prevalence in the combined sample. A total of 83 different haplotypes 
were identified in the complete study sample. The prevalence distribution was determined 
using all 9 SNPs for common haplotypes 1-5 whereas for more rare haplotypes 6-13 the 
figures represent combined pooled haplotypes based on the 2 SNPs, and deletion/insertion 
polymorphism to facilitate presentation (Table 1, Table 2 and Table 3; study V). The 
diversity of the LPH haplotypes (which reflecting the heterozygosity) in most populations 
varied between 60 (±0.03) to 89 (±0.03), the Utah sample showing the lowest value of 0.44 
(±0.04). 
 
Four major lactase non persistence haplotypes with a high frequency (>5%) (haplotypes 1-4) 
were observed in almost all populations tested (Table 2 and Figure 3; study V). Haplotype 
1-3 which account for majority of lactase non persistence alleles are highly divergent from 
the major haplotype of lactase persistence, haplotype 5 (Table 2 and Figure 3; study V), 
from haplotype 1 they differ at every SNP site tested. . In contrast to this, the haplotype 4 
differs from haplotype 5 only at the positions of the two critical variants (C/T-13910 and G/A-
22018). For lactase persistence haplotypes, one major haplotype distinctly predominates 
(haplotype 5) in almost all population tested, with only a few notably exceptions. In Komi 
and Mokshas, the lactase persistence haplotype 10, in which lactase persistence mutation is 
atypically found on background of the insertion allele, was observed at high frequency (10% 
and 11%).  
The information provides a picture of the relatively limited haplotype diversity among lactase 
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non persistence alleles, somewhat in contrast to our previous findings using microsatellites 
(Enattah et al. 2002). For example, in South Korea, Han Chinese, Somi balti and Kalash 
showing a fixation for lactase non-persistence alleles, the haplotypes 1-4 explain 76- 97% of 
haplotype diversity in these populations. Since haplotypes 2, and 3 differ only in one SNP, 
this would imply only two major lactase non persistent alleles, a highly restricted number of 
ancestral alleles (Table 2 and Figure 3; study V). This is not too surprising since SNP 
profiles reflect the haploblocks of old alleles whereas the multiallelic markers expose more 
recent mutational events of the markers. 
 
 
In our search for the population which could be represent the place of origin of lactase 
persistent variant and thus provide hints about the evolutionary history of this mutation, we 
aimed to find populations with a high frequencies and maximal diversity of lactase persistent 
specific allelic haplotypes. Trans-Ural populations were found to fulfill these criteria (Table 
2 and Figure 3; Study V). Haplotype 4 represents a lactase non persistent haplotype 
differing from lactase persistent haplotypes at only two positions, the variants most tightly 
associated with lactase persistence. This haplotype could be considered as pre-lactase 
persistence and represent allelic background on which lactase persistence mutation(s) 
occurred. However, we cannot exclude the possibility that this haplotype could have arisen 
from haplotype 5 as a result of a gene conversion event.  
 
We monitored the frequency pattern of the haplotype 4 in our global populations to assess 
how and when the lactase persistence alleles were introduced. The highest prevalence of this  
haplotype was found in Trans- Ural populations, in the eastern part of Urals, among, among 
Ob-Ugric speakers, reaching the prevalence of 33%. This population has less than 5% 
frequency of lactase persistence allele. In the Western part of Ural, the populations located in 
the region between the Ural mountain and Volga river, the frequency of haplotype 4 is as 
high as 35% among Komi, Udmurtains, Lapp Saami. The high prevalence of haplotype 4 
extends to Han Chinese (36%), to populations totally lacking the lactase persistence allele. 
The high prevalence of this allelic background could also exist in South Korea, in which the 
pooled haplotype 7 (1xx1xx1xx) (Table 2; study V) in this population representing only one 
ancestral haplotype (122122122) (22%) carried the same variation of haplotype 4 but lacked 
the deletion polymorphism (data not shown).  
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The pooled lactase persistence haplotypes 9 and 10 (which could be considered as earliest 
haplotypes where lactase persistence variants occurred on an insertion polymorphism 
background (ancestral lactase non persistence) allele) showed the highest frequencies (5-
15%) in the populations of Western slope of Ural mountains like Komi, Udmurtians, 
Mokshas and Erzayas populations. For example the pooled haplotype 10 in Mokshas 
represents only one haplotype (111211211) with 11% frequency. This haplotype carries 
lactase persistence variants on the haplotype background characteristic of lactase 
nonpersistence haplotype 1 (111111111). This result could imply that the route to lactase 
persistence could have occurred through two lineages in human history:  one lineage is 
represented on the background of haplotypes 1 and 2 resulting in the less frequent lactase 
persistence haplotypes 9 and 10. This lineage would represent a very early event (Figure 4; 
study V). The other lineage originates from the background of lactase non persistence 
haplotype 4, resulting in the most common lactase persistence haplotype 5. This lactase 
persistence mutation obviously occurred more recent in history (Figure 4 and Table 2; 
study V).  
 
To investigate the phylogenetic relationship between haplotypes, we constructed the 
Minimum Spanning Tree (MST) of the haplotypes from the matrix of pairwise distances 
calculated between all pairs of haplotypes using Arelquin program (Figure 4; study V) and 
the tree was depicted using TreeView program. The major haplotypes carrying lactase non 
persistent allele are shown in yellow (haplotypes1-3) and red (haplotype 4), the major 
haplotypes carrying both lactase persistent variants are shown in green (haplotype 5) (Figure 
4 and Table 2; study V). The other haplotypes were pooled based on 2 SNPs (lactase 
variants: C/T-13910 and G/A-22018) and deletion/insertion polymorphism of intron one of the 
LPH gene (Table 2; study V). The color codes for pooled lactase non-persistence and 
persistence haplotypes are shown in Figure 4  and Table 2 of study V.  
 
There are two common lactase non-persistent haplotypes 1, 2 differing by only one 
mutational step and both these haplotypes are found in the sequence of all primates 
(Chimpanzee, Orangeutans, Gorilla Gorilla, and Rhesus Monkey). Based on the primate 
haplotype the tree can be rooted for lactase non persistence haplotypes 1 as ancestral 
haplotype. Lactase persistent haplotype 5 is highly divergent from haplotype 1, they differ for 
every SNP (n=9) tested. The lactase non-persistence haplotypes 1, 2 are highly divergent 
from lactase non-persistent haplotype 4 and the frequency of intervening haplotypes between 
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them are low,  being most probably lost due to the drift. Although the most common lactase 
persistence haplotype seen in all population tested is haplotype 5, we detected traces of other 
lineage of lactase persistence haplotype (haplotypes 10a-10b-10c-6a). The option that 
haplotype 5 originates from this relatively rare lineage still remains especially if haplotype 4 
has risen via gene conversion from haplotype 5. In both cases the trans Uralic populations 
have the highest prevalence of haplotype 4 as well as the lineage10a-10b-10c-6a (Figures 3 
and 4; study V) which makes this geographical region the most likely focal origin of the most 
common lactase persistence allele, representing haplotype 5. Finally, the star pattern 
surrounding haplotypes 1, 2 and 4 is consistent with a history of population expansion. 
 
We used linkage disequilibrium to estimate the number of generations to the most recent 
common ancestor (MRCA) of lactase persistence trait in Finnish population by analyzing the 
frequency of the allele 2 of the marker D2S3014, which showing highest LD with the trait in 
our previous family study (Bersaglieri et al. 2004). Assuming a 20-years generation time, this 
estimate would indicate that the MRCA dates back between 3200 (95 %CI; 1040-8000) to 
4400 (95% CI, 2260-9240) years ago without and with adopting Luria-Delbrűck genetic clock 
respectively (Table 9). This date is in good agreement with the history of nomadic tribes who 
came to Europe at that time from the east (Figure 3; study V) (Cavalli-Sforza 1994). This 
estimates are in good agreement with recent report in which the estimated date using 
Scandinavian families between 1625-3188 years ago and using CEPH between 2188-20650 
years (Bersaglieri et al. 2004). 
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Table 9. Estimation of the most common recent ancestor of the C/T-13910 variant of the 
Finnish population. 
a Based on the comparison of genetic and Physical maps of the interval D2S1334-D2S2196, 
which contains the variant from Marshfield Map (Medical Research foundation). b Inferred 
from approximate physical distance between markers D2S3010-D2S2196 (Fig. 2) to genetic 
distance from Marshfield genetic map c The median Θ obtained from the previous 
conversions d linkage disequilibrium index calculated as described in the method e g and gc are 
estimated ages (generations) obtained using of Risch algorithm, without and with Luria-
Delbrűck correction of the genetic clock respectively as described in the methods. We used a 
generation time =30 years. 
 
 
4.3 The proposed history of lactase persistence 
 
The presence of highly divergent haplotypes like the major lactase persistence haplotype 
(haplotype 5) and the lactase non persistent haplotype 4 has been recently shown to be very 
common in human genome, and it is referred as yin yang haplotype (Zhang et al. 2003). In 
the analysis of 175 random genomic regions in humans, the proportion of the genome 
spanned by yin yang haplotypes is suggested to be 75-85%. Interestingly, this could be 
explained by strictly neutral evolution in a well-mixed populations by coalescence 
Marker D2S3014 
Allele 2 
Distance           Kb       31 
Conversion factor 1.2cM=1Mba 1cM=0.42Mbb 1cM=0.625Mbc 
 Θ 0.00037 0.00074 0.00049 
                 Pper (N) 0.939 (33) 
                 Pnon-per(N) 0.192 (52) 
LD  (δ)d 0.924 
Estimated agee    
                 g (95%CI) 
 
213 (69-529)  
6390 (2070-15870)    
 
107 (35-264)   
3210 (1050-7920)    
 
160 (52-400)      
4800 (1560-12000)          
                gc (95%CI) 277 (160-593) 
8310 (4800-17790) 
163 (91-320) 
4890 (2730-9600) 
  220 (113-461) 
6600 (3390-13830) 
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simulations (Zhang et al. 2003). 
 
The unsolved issue of selection against lactase nonpersistence allele could result in a biased 
interpretation of population history. Despite this problem, a plausible hypothesis for the 
origin of lactase persistence, based on the frequency and diversity of the haplotype the age of 
lactase persistence allele could be estimated based on LD and incorporating the genetic, 
archaeological and historical evidences (Simoons 1978; Guglielmino et al. 1990; Sokal et al. 
1992; Barbujani et al. 1995; Weng and Sokal 1995; Holden and Mace 1997; Dudd and 
Evershed 1998; Semino et al. 2000; Derbeneva et al. 2002).  
 
We propose that the genetic differentiation for lactase persistence has occurred within the 
pastoral nomads in Central Asia adjacent to the eastern slope of the Ural 4800-6600 years ago 
(supported by high frequency of pre lactase persistence haplotype 4 in this region) (Figure 3; 
study V). These nomads moved west towards the western slope of Ural and in this location 
the mutation for lactase persistence allele has most likely arisen within pastoral nomads in the 
region between the Volga and the Urals, north of the Caucasus and the Black Sea (this is 
supported by high frequency of haplotype 4 and haplotype diversity of lactase persistence 
alleles in this region). This scenario is in good agreement with the hypothesis of Gimbutas 
who suggested that there was a westward expansion from the Kurgan area above the 
Caucasus, of pastoral nomads speaking Indo-European languages between 2500 and 1500 
B.C. (Figure 3; study V) (Cavalli-Sforza 1994).  
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CONCLUDING REMARKS 
 
The first publication of this thesis presents the localization and fine mapping of the congenital 
lactase deficiency (CLD) locus on chromosome 2q21, using linkage, linkage disequilibrium 
and ancestral haplotype analyses, between markers D2S314-D2S2385, about 1 Mb 5´ of LPH 
gene. The result was a clear indication that two separate genetic loci underlie congenital 
lactase deficiency and lactase persistence residing on chromosome 2q21. This result was also 
confirmed by mutational analysis of the cDNA of LPH gene in one CLD patient by an Italian 
group, which reveal no sequence changes in CLD, and no correlation between CLD and the 
variants C/T-13910 and G/A-22018 associated with lactase persistence. The work to identify the 
CLD culprit is underway and will be reported elsewhere. 
 
The second publication of the thesis presents the localization and identification of the 
mutations underlies one of the most common conditions in human lactase persistence/ non 
persistence trait. Initially we localized the locus flanking the LPH gene between markers 
D2S114-D2S2385 in nine extended Finnish families. Based on linkage disequilibrium and 
haplotype analysis we restricted the region to 47 kb interval between markers D2S3014-
D2S3012. Sequence analysis revealed two variants, C/T-13910 and G/A-22018, correlating with 
lactase persistence/non persistence trait in both families and case-control study materials.  
Analysis of both SNPs in different populations gives supportive evidence that SNP C/T-13910  
is most probably the causing variant of lactase persistence trait, in which one major haplotype 
carrying the persistent T-13910 is present in all populations studied (Hollox et al. 2001; Enattah 
et al. 2002). The analysis of disacchridase activities in these samples shows a strong 
statistically significant correlation between lactase activity and trimodal distribution of the 
C/T-13910 genotypes (P<0.0001). In addition our data show that age per se has no significant 
effect on the disaccharidase activity in adults, aged between 18-83 years. This result enabled 
us to test the potential association between lactase persistence with diabetes and other clinical 
conditions. Finally, we analyzed the diversity of critical 30 kb region in 36 populations. 
Based on haplotype analysis, genetic variations, and LD intervals we propose that the region 
adjacent to the Eastern and Western slopes of Ural is the most likely region of origin for the 
lactase persistence mutation(s). The major lactase persistent haplotype most probably 
originated in nomadic population tribe between the western slope of Urals and Volga River 
some (4800-6600 years ago) (Cavalli-Sforza 1994) and the mutation then spread with 
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migration of tribes westward towards Europe in the direction from southeast to northwest and 
in the southeast ward towards Western Asia and Middle East. The presence of one mutation 
in many populations underlies the lactase persistence/non persistence trait enabled us to 
develop a DNA based diagnostic test for this condition. While the work of this thesis was 
proceeding, the functional convincing evidence for SNP C/T-13910 emerged in the literature 
(Olds and Sibley 2003; Troelsen et al. 2003b).  Analysis of the critical DNA region in various 
populations has shed light on the possible place of origin of the mutation and paved the way 
to study the effect of different evolutionary forces shaping the diversity in this region such as 
the role of selection, genetic drift and population structure. 
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